000141332912/312022Q1FALSE00014133292022-01-012022-03-310001413329us-gaap:CommonStockMember2022-01-012022-03-310001413329pm:A2.375Notesdue2022Member2022-01-012022-03-310001413329pm:A2.500Notesdue20221Member2022-01-012022-03-310001413329pm:A2.500Notesdue20222Member2022-01-012022-03-310001413329pm:A2.625Notesdue2023Member2022-01-012022-03-310001413329pm:A2.125Notesdue2023Member2022-01-012022-03-310001413329pm:A3.600Notesdue2023Member2022-01-012022-03-310001413329pm:A2.875Notesdue20241Member2022-01-012022-03-310001413329pm:A2.875Notesdue20242Member2022-01-012022-03-310001413329pm:A0.625Notesdue2024Member2022-01-012022-03-310001413329pm:A3.250Notesdue2024Member2022-01-012022-03-310001413329pm:A2.750Notesdue2025Member2022-01-012022-03-310001413329pm:A3.375Notesdue2025Member2022-01-012022-03-310001413329pm:A2.750Notesdue2026Member2022-01-012022-03-310001413329pm:A2.875Notesdue2026Member2022-01-012022-03-310001413329pm:A0.125Notesdue2026Member2022-01-012022-03-310001413329pm:A3.125Notesdue2027Member2022-01-012022-03-310001413329pm:A3.125Notesdue2028Member2022-01-012022-03-310001413329pm:A2.875Notesdue2029Member2022-01-012022-03-310001413329pm:A3.375Notesdue2029Member2022-01-012022-03-310001413329pm:A0.800Notesdue2031Member2022-01-012022-03-310001413329pm:A3.125Notesdue2033Member2022-01-012022-03-310001413329pm:A2.000Notesdue2036Member2022-01-012022-03-310001413329pm:A1.875Notesdue2037Member2022-01-012022-03-310001413329pm:A6.375Notesdue2038Member2022-01-012022-03-310001413329pm:A1.450Notesdue2039Member2022-01-012022-03-310001413329pm:A4.375Notesdue2041Member2022-01-012022-03-310001413329pm:A4.500Notesdue2042Member2022-01-012022-03-310001413329pm:A3.875Notesdue2042Member2022-01-012022-03-310001413329pm:A4.125Notesdue2043Member2022-01-012022-03-310001413329pm:A4.875Notesdue2043Member2022-01-012022-03-310001413329pm:A4.250Notesdue2044Member2022-01-012022-03-3100014133292022-04-22xbrli:sharesiso4217:USD00014133292021-01-012021-03-31iso4217:USDxbrli:shares00014133292022-03-3100014133292021-12-3100014133292020-12-3100014133292021-03-310001413329us-gaap:CommonStockMember2020-12-310001413329us-gaap:AdditionalPaidInCapitalMember2020-12-310001413329us-gaap:RetainedEarningsMember2020-12-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001413329us-gaap:TreasuryStockMember2020-12-310001413329us-gaap:NoncontrollingInterestMember2020-12-310001413329us-gaap:RetainedEarningsMember2021-01-012021-03-310001413329us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001413329us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001413329us-gaap:TreasuryStockMember2021-01-012021-03-310001413329us-gaap:CommonStockMember2021-03-310001413329us-gaap:AdditionalPaidInCapitalMember2021-03-310001413329us-gaap:RetainedEarningsMember2021-03-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001413329us-gaap:TreasuryStockMember2021-03-310001413329us-gaap:NoncontrollingInterestMember2021-03-310001413329us-gaap:CommonStockMember2021-12-310001413329us-gaap:AdditionalPaidInCapitalMember2021-12-310001413329us-gaap:RetainedEarningsMember2021-12-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001413329us-gaap:TreasuryStockMember2021-12-310001413329us-gaap:NoncontrollingInterestMember2021-12-310001413329us-gaap:RetainedEarningsMember2022-01-012022-03-310001413329us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001413329us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001413329us-gaap:TreasuryStockMember2022-01-012022-03-310001413329us-gaap:CommonStockMember2022-03-310001413329us-gaap:AdditionalPaidInCapitalMember2022-03-310001413329us-gaap:RetainedEarningsMember2022-03-310001413329us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001413329us-gaap:TreasuryStockMember2022-03-310001413329us-gaap:NoncontrollingInterestMember2022-03-310001413329pm:A2017PerformanceIncentivePlanMember2017-05-310001413329pm:A2017PerformanceIncentivePlanMember2022-03-310001413329pm:A2017NonEmployeeDirectorsPlanMember2017-05-31xbrli:pure0001413329pm:A2017NonEmployeeDirectorsPlanMember2022-03-310001413329us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001413329us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001413329us-gaap:RestrictedStockUnitsRSUMember2022-03-31pm:year0001413329us-gaap:RestrictedStockUnitsRSUMemberpm:GrantDateFairValueMember2022-01-012022-03-310001413329pm:FairValueMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001413329us-gaap:PerformanceSharesMember2022-01-012022-03-310001413329us-gaap:PerformanceSharesMember2022-03-310001413329us-gaap:PerformanceSharesMember2021-03-31pm:performanceMetric0001413329srt:MinimumMemberus-gaap:PerformanceSharesMember2022-01-012022-03-310001413329us-gaap:PerformanceSharesMembersrt:MaximumMember2022-01-012022-03-310001413329pm:PerformanceShareUnitsOtherPerformanceMetricsMember2022-01-012022-03-310001413329pm:PerformanceShareUnitsTSRPerformanceMetricMember2022-01-012022-03-310001413329us-gaap:PerformanceSharesMember2021-01-012021-03-310001413329pm:PerformanceShareUnitsOtherPerformanceMetricsMember2021-01-012021-03-310001413329pm:PerformanceShareUnitsTSRPerformanceMetricMember2021-01-012021-03-310001413329us-gaap:PerformanceSharesMemberpm:GrantDateFairValueMember2022-01-012022-03-310001413329pm:FairValueMemberus-gaap:PerformanceSharesMember2022-01-012022-03-310001413329us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-03-310001413329us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-03-310001413329pm:PostemploymentBenefitPlansMember2022-01-012022-03-310001413329pm:PostemploymentBenefitPlansMember2021-01-012021-03-310001413329us-gaap:PostretirementBenefitCostsMember2022-01-012022-03-310001413329us-gaap:PostretirementBenefitCostsMember2021-01-012021-03-310001413329pm:EuropeanUnionSegmentMember2021-12-310001413329pm:EasternEuropeSegmentMember2021-12-310001413329pm:MiddleEastAfricaSegmentMember2021-12-310001413329pm:SouthSoutheastAsiaSegmentMember2021-12-310001413329pm:EastAsiaAustraliaSegmentMember2021-12-310001413329pm:AmericasSegmentMember2021-12-310001413329pm:OtherSegmentMember2021-12-310001413329pm:EuropeanUnionSegmentMember2022-01-012022-03-310001413329pm:EasternEuropeSegmentMember2022-01-012022-03-310001413329pm:MiddleEastAfricaSegmentMember2022-01-012022-03-310001413329pm:SouthSoutheastAsiaSegmentMember2022-01-012022-03-310001413329pm:EastAsiaAustraliaSegmentMember2022-01-012022-03-310001413329pm:AmericasSegmentMember2022-01-012022-03-310001413329pm:OtherSegmentMember2022-01-012022-03-310001413329pm:EuropeanUnionSegmentMember2022-03-310001413329pm:EasternEuropeSegmentMember2022-03-310001413329pm:MiddleEastAfricaSegmentMember2022-03-310001413329pm:SouthSoutheastAsiaSegmentMember2022-03-310001413329pm:EastAsiaAustraliaSegmentMember2022-03-310001413329pm:AmericasSegmentMember2022-03-310001413329pm:OtherSegmentMember2022-03-310001413329pm:EuropeanUnionSegmentMember2021-12-312021-12-310001413329us-gaap:TrademarksMember2022-01-012022-03-310001413329us-gaap:TrademarksMember2022-03-310001413329us-gaap:TrademarksMember2021-12-310001413329us-gaap:DevelopedTechnologyRightsMember2022-01-012022-03-310001413329us-gaap:DevelopedTechnologyRightsMember2022-03-310001413329us-gaap:DevelopedTechnologyRightsMember2021-12-310001413329us-gaap:OtherIntangibleAssetsMember2022-01-012022-03-310001413329us-gaap:OtherIntangibleAssetsMember2022-03-310001413329us-gaap:OtherIntangibleAssetsMember2021-12-310001413329pm:TrademarksandDistributionNetworksMember2022-01-012022-03-310001413329us-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2022-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberpm:OtherAccruedLiabilitiesMember2022-03-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberpm:OtherAccruedLiabilitiesMember2021-12-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMember2022-03-310001413329us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMember2021-12-310001413329us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberpm:OtherAccruedLiabilitiesMember2022-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberpm:OtherAccruedLiabilitiesMember2021-12-310001413329us-gaap:NondesignatedMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMember2022-03-310001413329us-gaap:NondesignatedMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMember2021-12-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMember2022-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMember2021-12-310001413329us-gaap:ForeignExchangeContractMember2021-12-310001413329us-gaap:ForeignExchangeContractMember2022-01-012022-03-310001413329us-gaap:ForeignExchangeContractMember2021-01-012021-03-310001413329us-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001413329us-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2022-01-012022-03-310001413329us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2021-01-012021-03-310001413329us-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2022-01-012022-03-310001413329us-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2021-01-012021-03-310001413329us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001413329us-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001413329us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-01-012022-03-310001413329us-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2021-01-012021-03-310001413329us-gaap:NondesignatedMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001413329us-gaap:NondesignatedMemberus-gaap:InterestExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2022-01-012022-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberpm:MarketingAdministrationAndResearchCostsMember2021-01-012021-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310001413329us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001413329us-gaap:ForeignExchangeContractMembersrt:MaximumMember2022-01-012022-03-310001413329us-gaap:FairValueHedgingMember2022-03-310001413329pm:ForeignDebtMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-03-310001413329pm:ForeignDebtMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-03-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-03-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-03-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-03-310001413329us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-03-310001413329us-gaap:OtherInvestmentCompaniesMemberus-gaap:FairValueInputsLevel1Member2022-03-31pm:segment0001413329us-gaap:OperatingSegmentsMemberpm:EuropeanUnionSegmentMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:EuropeanUnionSegmentMember2021-01-012021-03-310001413329pm:EasternEuropeSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001413329pm:EasternEuropeSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:MiddleEastAfricaSegmentMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:MiddleEastAfricaSegmentMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:SouthSoutheastAsiaSegmentMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:SouthSoutheastAsiaSegmentMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:EastAsiaAustraliaSegmentMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:EastAsiaAustraliaSegmentMember2021-01-012021-03-310001413329pm:AmericasSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001413329pm:AmericasSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:EuropeanUnionSegmentMemberpm:CombustibleProductsMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:EuropeanUnionSegmentMemberpm:CombustibleProductsMember2021-01-012021-03-310001413329pm:EasternEuropeSegmentMemberus-gaap:OperatingSegmentsMemberpm:CombustibleProductsMember2022-01-012022-03-310001413329pm:EasternEuropeSegmentMemberus-gaap:OperatingSegmentsMemberpm:CombustibleProductsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:MiddleEastAfricaSegmentMemberpm:CombustibleProductsMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:MiddleEastAfricaSegmentMemberpm:CombustibleProductsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:SouthSoutheastAsiaSegmentMemberpm:CombustibleProductsMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:SouthSoutheastAsiaSegmentMemberpm:CombustibleProductsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:CombustibleProductsMemberpm:EastAsiaAustraliaSegmentMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:CombustibleProductsMemberpm:EastAsiaAustraliaSegmentMember2021-01-012021-03-310001413329pm:AmericasSegmentMemberus-gaap:OperatingSegmentsMemberpm:CombustibleProductsMember2022-01-012022-03-310001413329pm:AmericasSegmentMemberus-gaap:OperatingSegmentsMemberpm:CombustibleProductsMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:CombustibleProductsMember2022-01-012022-03-310001413329us-gaap:OperatingSegmentsMemberpm:CombustibleProductsMember2021-01-012021-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:EuropeanUnionSegmentMember2022-01-012022-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:EuropeanUnionSegmentMember2021-01-012021-03-310001413329pm:ReducedRiskProductsMemberpm:EasternEuropeSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001413329pm:ReducedRiskProductsMemberpm:EasternEuropeSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:MiddleEastAfricaSegmentMember2022-01-012022-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:MiddleEastAfricaSegmentMember2021-01-012021-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:SouthSoutheastAsiaSegmentMember2022-01-012022-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:SouthSoutheastAsiaSegmentMember2021-01-012021-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:EastAsiaAustraliaSegmentMember2022-01-012022-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMemberpm:EastAsiaAustraliaSegmentMember2021-01-012021-03-310001413329pm:AmericasSegmentMemberpm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001413329pm:AmericasSegmentMemberpm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001413329pm:ReducedRiskProductsMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001413329pm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMembercountry:CApm:SmokingAndHealthClassActionsMember2015-05-272015-05-27pm:manufacturer0001413329pm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberus-gaap:JudicialRulingMembercountry:CApm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Memberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-27iso4217:CAD0001413329pm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberus-gaap:JudicialRulingMembercountry:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-27pm:plaintiff0001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:AppellateRulingMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMember2015-10-012015-10-300001413329country:CApm:AppellateRulingMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMemberpm:ImperialTobaccoLtd.Member2015-10-012015-10-300001413329pm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberus-gaap:JudicialRulingMembercountry:CApm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Memberpm:SmokingAndHealthClassActionsMember2019-03-012019-03-010001413329pm:ConseilQuebecoisSurLeTabacEtLaSanteandJeanYvesBlaisMemberus-gaap:JudicialRulingMembercountry:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:SmokingAndHealthClassActionsMember2019-03-012019-03-010001413329us-gaap:JudicialRulingMembercountry:CApm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Memberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMember2019-03-012019-03-010001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:AppellateRulingMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMember2019-03-012019-03-010001413329country:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:AppellateRulingMemberpm:CeciliaLetourneauConseilQuebecoisSurLaTabacEtLaSanteandJeanYvesBlaisCasesMemberpm:SmokingAndHealthClassActionsMember2019-10-012019-12-310001413329country:CApm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-270001413329us-gaap:JudicialRulingMembercountry:CApm:ImperialTobaccoLtd.RothmansBensonAndHedgesInc.AndJTIMacdonaldCorp.Memberpm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-270001413329us-gaap:JudicialRulingMembercountry:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMember2015-05-272015-05-270001413329us-gaap:JudicialRulingMembercountry:CApm:RothmansBensonAndHedgesInc.RBHMemberpm:CeciliaLetourneauMemberpm:SmokingAndHealthClassActionsMember2019-03-012019-03-010001413329country:CApm:AdamsMemberus-gaap:PendingLitigationMember2009-07-102009-07-10pm:cigarette0001413329pm:SuzanneJacklinMembercountry:CAus-gaap:PendingLitigationMember2012-06-202012-06-200001413329pm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-31pm:litigationCase0001413329pm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2021-03-310001413329pm:SmokingAndHealthClassActionsMemberpm:CombustibleProductsMember2022-03-310001413329pm:SmokingAndHealthClassActionsMemberpm:CombustibleProductsMember2021-03-310001413329pm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2022-03-310001413329pm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2021-03-310001413329pm:LabelRelatedClassActionMemberpm:CombustibleProductsMember2022-03-310001413329pm:LabelRelatedClassActionMemberpm:CombustibleProductsMember2021-03-310001413329pm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2022-03-310001413329pm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMember2021-03-310001413329pm:PublicCivilActionsMemberpm:CombustibleProductsMember2022-03-310001413329pm:PublicCivilActionsMemberpm:CombustibleProductsMember2021-03-310001413329pm:CaseDecidedInFavorOfPlaintiffMember2022-03-310001413329pm:CasesRemainingOnAppealMember2022-03-310001413329us-gaap:JudicialRulingMembercountry:ARpm:HugoLespadaMemberpm:SmokingAndHealthIndividualActionsMember2016-08-052016-08-05iso4217:ARS0001413329us-gaap:JudicialRulingMemberpm:ClaudiaMilanoMembercountry:ARpm:SmokingAndHealthIndividualActionsMember2021-06-172021-06-170001413329us-gaap:JudicialRulingMemberpm:ClaudiaMilanoMembercountry:ARpm:SmokingAndHealthIndividualActionsMember2021-07-022021-07-020001413329us-gaap:JudicialRulingMemberpm:ClaudiaMilanoMembercountry:ARpm:SmokingAndHealthIndividualActionsMember2021-12-162021-12-160001413329country:ARpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-310001413329country:BRpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-310001413329country:CApm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-310001413329pm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMembercountry:CL2022-03-310001413329country:PHpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-310001413329country:TRpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-310001413329pm:ScotlandMemberpm:IndividualSmokingAndHealthCasesMemberpm:CombustibleProductsMember2022-03-310001413329pm:IndividualSmokingAndHealthCasesMembercountry:USpm:CombustibleProductsMember2022-03-310001413329country:BRpm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2022-03-310001413329country:CApm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2022-03-310001413329country:KRpm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2022-03-310001413329country:NGpm:HealthCareCostRecoveryActionsMemberpm:CombustibleProductsMember2022-03-310001413329country:NGpm:HealthCareCostRecoveryActionsMemberus-gaap:PendingLitigationMemberpm:TheAttorneyGeneralOfLagosStateMember2008-03-132008-03-130001413329country:NGpm:TheAttorneyGeneralOfKanoStateMemberpm:HealthCareCostRecoveryActionsMemberus-gaap:PendingLitigationMember2007-05-092007-05-090001413329pm:TheAttorneyGeneralOfGombeStateMembercountry:NGpm:HealthCareCostRecoveryActionsMemberus-gaap:PendingLitigationMember2008-10-172008-10-170001413329country:NGpm:TheAttorneyGeneralOfOyoStateMemberpm:HealthCareCostRecoveryActionsMemberus-gaap:PendingLitigationMember2007-05-252007-05-250001413329country:NGpm:TheAttorneyGeneralOfOgunStateMemberpm:HealthCareCostRecoveryActionsMemberus-gaap:PendingLitigationMember2008-02-262008-02-260001413329country:KRpm:HealthCareCostRecoveryActionsMember2014-04-142014-04-14pm:patient0001413329pm:IndividualLabelRelatedCasesMembercountry:ITpm:CombustibleProductsMember2022-03-310001413329pm:IndividualLabelRelatedCasesMemberpm:CombustibleProductsMembercountry:CL2022-03-310001413329pm:PublicCivilActionsMembercountry:VEpm:CombustibleProductsMember2022-03-310001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:THus-gaap:PendingLitigationMember2016-01-182016-01-18pm:defendantiso4217:THB0001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2019-11-012019-11-300001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2017-01-262017-01-260001413329pm:OtherLitigationMemberpm:TheDepartmentofSpecialInvestigationsoftheGovernmentofThailandMembercountry:TH2020-03-012020-03-310001413329country:KRpm:OtherLitigationMemberpm:TheSouthKoreanBoardOfAuditAndInspectionMember2016-11-012017-03-31iso4217:KRW0001413329country:KRpm:OtherLitigationMemberpm:TheSouthKoreanBoardOfAuditAndInspectionMember2016-01-012016-12-310001413329country:KRpm:OtherLitigationMemberpm:TheSouthKoreanBoardOfAuditAndInspectionMember2017-01-012017-03-310001413329country:KRpm:OtherLitigationMemberpm:TheSouthKoreanBoardOfAuditAndInspectionMember2020-01-012020-01-310001413329country:KRpm:OtherLitigationMemberpm:TheSouthKoreanBoardOfAuditAndInspectionMember2020-06-012020-06-300001413329pm:SaudiArabiaCustomsGeneralAuthorityCaseMemberpm:OtherLitigationMembercountry:SA2022-03-31iso4217:SAR0001413329pm:MiddleEastAfricaSegmentMembercountry:SA2022-01-012022-03-310001413329pm:CanadianGovernmentMember2020-10-170001413329pm:CanadianGovernmentMember2022-03-310001413329pm:MedicagoIncMemberpm:PhilipMorrisInvestmentBVMember2021-12-310001413329pm:MedicagoIncMemberpm:PhilipMorrisInvestmentBVMember2022-03-310001413329srt:ScenarioForecastMembersrt:MinimumMember2022-01-012022-12-310001413329srt:ScenarioForecastMembersrt:MaximumMember2022-01-012022-12-310001413329srt:MinimumMember2022-01-012022-03-310001413329srt:MaximumMember2022-01-012022-03-3100014133292021-10-012021-10-31iso4217:IDR0001413329pm:UsDollarNotesMembersrt:MinimumMember2022-03-310001413329pm:UsDollarNotesMembersrt:MaximumMember2022-03-310001413329pm:UsDollarNotesMember2022-01-012022-03-310001413329pm:UsDollarNotesMember2022-03-310001413329pm:UsDollarNotesMember2021-12-310001413329pm:EuroNotesPayableMembersrt:MinimumMemberpm:ForeignCurrencyObligationsMember2022-03-310001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMembersrt:MaximumMember2022-03-310001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2022-01-012022-03-310001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2022-03-310001413329pm:EuroNotesPayableMemberpm:ForeignCurrencyObligationsMember2021-12-310001413329pm:SwissFrancNotesMemberpm:ForeignCurrencyObligationsMember2022-03-310001413329pm:SwissFrancNotesMemberpm:ForeignCurrencyObligationsMember2021-12-310001413329us-gaap:NotesPayableOtherPayablesMemberpm:ForeignCurrencyObligationsMember2022-01-012022-03-310001413329us-gaap:NotesPayableOtherPayablesMemberpm:ForeignCurrencyObligationsMember2022-03-310001413329us-gaap:NotesPayableOtherPayablesMemberpm:ForeignCurrencyObligationsMember2021-12-310001413329us-gaap:FairValueInputsLevel1Member2022-03-310001413329us-gaap:FairValueInputsLevel2Member2022-03-310001413329pm:ThreeHundredSixtyFourDayRevolvingCreditExpiringJanuary312023Member2022-03-310001413329pm:MultiYearRevolvingCreditFacilityExpiringFebruary102026Member2022-03-310001413329pm:MultiYearRevolvingCreditFacilityExpiringSeptember292026Member2022-03-310001413329pm:MultiYearRevolvingCreditFacilityExpiringFebruary102027Member2022-01-280001413329us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001413329us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001413329us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001413329us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310001413329us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001413329us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310001413329us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310001413329us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001413329us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310001413329pm:EquityMethodInvestmentGoodwillMember2022-03-310001413329pm:EquityMethodInvestmentGoodwillMember2021-12-3100014133292021-01-012021-12-310001413329pm:MegapolisMember2022-03-310001413329pm:EITAMember2022-03-310001413329pm:STAEMMember2022-03-310001413329pm:EITAMemberpm:STAEMMember2022-03-310001413329pm:ManagementEtDeveloppementDesActifsEtDesRessourcesHoldingMADARHoldingMemberpm:STAEMMember2022-03-310001413329pm:RothmansBensonAndHedgesInc.RBHMember2019-03-220001413329pm:TTIMemberpm:PMMMember2022-03-310001413329pm:IPMIndiaMember2022-03-310001413329pm:MegapolisMember2022-01-012022-03-310001413329pm:MegapolisMember2021-01-012021-03-310001413329pm:OtherRelatedPartyMember2022-01-012022-03-310001413329pm:OtherRelatedPartyMember2021-01-012021-03-310001413329pm:MegapolisMember2022-03-310001413329pm:MegapolisMember2021-12-310001413329pm:OtherRelatedPartyMember2022-03-310001413329pm:OtherRelatedPartyMember2021-12-310001413329us-gaap:ContractTerminationMember2021-01-012021-03-310001413329us-gaap:EmployeeSeveranceMember2021-01-012021-03-310001413329pm:OrganizationalDesignOptimizationMember2021-12-31pm:employee0001413329us-gaap:EmployeeSeveranceMemberpm:OrganizationalDesignOptimizationMember2021-12-310001413329pm:OrganizationalDesignOptimizationMemberpm:AssetImpairmentMember2021-12-310001413329us-gaap:OperatingSegmentsMemberus-gaap:EuropeanUnionMemberus-gaap:EmployeeSeveranceMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberpm:EasternEuropeMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMemberpm:MiddleEastAndAfricaMember2021-01-012021-03-310001413329us-gaap:OperatingSegmentsMemberpm:SouthAndSoutheastAsiaMemberus-gaap:EmployeeSeveranceMember2021-01-012021-03-310001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-01-012021-03-310001413329pm:AmericasSegmentMemberus-gaap:OperatingSegmentsMemberus-gaap:EmployeeSeveranceMember2021-01-012021-03-310001413329pm:EastAsiaAndAustraliaMemberus-gaap:OperatingSegmentsMemberus-gaap:ContractTerminationMember2021-01-012021-03-310001413329srt:ScenarioForecastMember2022-01-012022-12-310001413329pm:NoncontrollingInterestPurchasePhilipMorrisTtnMamulleriSanayiVeTicaretAMember2022-01-050001413329pm:NoncontrollingInterestPurchasePhilipMorrisPazarlamaVeSatAMember2022-01-050001413329pm:NoncontrollingInterestPurchaseMember2022-01-012022-03-310001413329pm:NoncontrollingInterestPurchaseMember2022-03-310001413329pm:AGSnusAktieselskabMember2021-05-060001413329pm:AGSnusAktieselskabMember2021-05-062021-05-060001413329pm:FertinPharmaASMember2021-09-150001413329pm:FertinPharmaASMember2021-09-152021-09-15iso4217:DKK0001413329pm:FertinPharmaASMemberpm:CashConsiderationMember2021-09-152021-09-150001413329pm:FertinPharmaASMemberpm:ConsiderationForPaymentToSettleIndebtednessMember2021-09-152021-09-150001413329pm:FertinPharmaASMembersrt:MinimumMember2021-09-152021-09-150001413329pm:FertinPharmaASMembersrt:MaximumMember2021-09-152021-09-150001413329pm:VecturaGroupPlcMember2021-09-15iso4217:GBPxbrli:shares0001413329pm:VecturaGroupPlcMember2021-12-310001413329pm:VecturaGroupPlcMember2021-09-152021-09-15iso4217:GBP0001413329srt:MinimumMemberpm:VecturaGroupPlcMember2021-09-152021-09-150001413329pm:VecturaGroupPlcMembersrt:MaximumMember2021-09-152021-09-150001413329pm:OtiTopicIncAssetAcquisitionMember2021-08-090001413329pm:OtiTopicIncAssetAcquisitionMember2021-08-092021-08-090001413329pm:OtiTopicIncAssetAcquisitionMember2021-07-012021-09-300001413329country:UA2022-03-310001413329country:UApm:WarInUkraineMember2022-03-310001413329country:UApm:WarInUkraineMember2022-01-012022-03-310001413329country:RUpm:WarInUkraineMember2022-03-310001413329country:RUpm:WarInUkraineMember2022-01-012022-03-310001413329pm:WarInUkraineMemberus-gaap:CostOfSalesMember2022-01-012022-03-310001413329pm:WarInUkraineMemberpm:MarketingAdministrationAndResearchCostsMember2022-01-012022-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One) 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-33708
Philip Morris International Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3435103
(State or other jurisdiction of
    incorporation or organization)
(I.R.S. Employer
    Identification No.)
120 Park Avenue New York New York 10017
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (917) 663-2000
Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:
Title of each class                     Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PM New York Stock Exchange
2.375% Notes due 2022 PM22B New York Stock Exchange
2.500% Notes due 2022 PM22 New York Stock Exchange
2.500% Notes due 2022 PM22C New York Stock Exchange
2.625% Notes due 2023 PM23 New York Stock Exchange
2.125% Notes due 2023 PM23B New York Stock Exchange
3.600% Notes due 2023 PM23A New York Stock Exchange
2.875% Notes due 2024 PM24 New York Stock Exchange
2.875% Notes due 2024 PM24C New York Stock Exchange
0.625% Notes due 2024 PM24B New York Stock Exchange
3.250% Notes due 2024 PM24A New York Stock Exchange
2.750% Notes due 2025 PM25 New York Stock Exchange
3.375% Notes due 2025 PM25A New York Stock Exchange
2.750% Notes due 2026 PM26A New York Stock Exchange
Title of each class                     Trading Symbol(s) Name of each exchange on which registered
2.875% Notes due 2026 PM26 New York Stock Exchange
0.125% Notes due 2026 PM26B New York Stock Exchange
3.125% Notes due 2027 PM27 New York Stock Exchange
3.125% Notes due 2028 PM28 New York Stock Exchange
2.875% Notes due 2029 PM29 New York Stock Exchange
3.375% Notes due 2029 PM29A New York Stock Exchange
0.800% Notes due 2031 PM31 New York Stock Exchange
3.125% Notes due 2033 PM33 New York Stock Exchange
2.000% Notes due 2036 PM36 New York Stock Exchange
1.875% Notes due 2037 PM37A New York Stock Exchange
6.375% Notes due 2038 PM38 New York Stock Exchange
1.450% Notes due 2039 PM39 New York Stock Exchange
4.375% Notes due 2041 PM41 New York Stock Exchange
4.500% Notes due 2042 PM42 New York Stock Exchange
3.875% Notes due 2042 PM42A New York Stock Exchange
4.125% Notes due 2043 PM43 New York Stock Exchange
4.875% Notes due 2043 PM43A New York Stock Exchange
4.250% Notes due 2044 PM44 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  þ        No  ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  þ        No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer    þ                        Accelerated filer              
Non-accelerated filer                             Smaller reporting company    ☐
                                    Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  þ
At April 22, 2022, there were 1,550,110,316 shares outstanding of the registrant’s common stock, no par value per share.
1

PHILIP MORRIS INTERNATIONAL INC.
TABLE OF CONTENTS
 
    Page No.
PART I -
Item 1.
Condensed Consolidated Statements of Earnings for the
Three Months Ended March 31, 2022 and 2021
3
Condensed Consolidated Statements of Comprehensive Earnings for the
Three Months Ended March 31, 2022 and 2021
4
Condensed Consolidated Balance Sheets at
March 31, 2022 and December 31, 2021
5 6
Condensed Consolidated Statements of Cash Flows for the
Three Months Ended March 31, 2022 and 2021
7 – 8
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the
Three Months Ended March 31, 2022 and 2021
9
10 43
Item 2.
44 92
Item 4.
PART II -
Item 1.
Item 1A.
Item 2.
Item 6.

In this report, “PMI,” “we,” “us” and “our” refer to Philip Morris International Inc. and its subsidiaries.

Trademarks and service marks in this report are the registered property of, or licensed by, the subsidiaries of Philip Morris International Inc. and are italicized.
2

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
  For the Three Months Ended March 31,
  2022 2021
Revenues including excise taxes $ 19,341  $ 19,355 
Excise taxes on products 11,595  11,770 
Net revenues 7,746  7,585 
Cost of sales (Note 18) 2,608  2,274 
Gross profit 5,138  5,311 
Marketing, administration and research costs (Notes 16 & 18) 1,802  1,849 
Amortization of intangibles 38  18 
Operating income 3,298  3,444 
Interest expense, net 154  167 
Pension and other employee benefit costs (Note 3) 28 
Earnings before income taxes 3,140  3,249 
Provision for income taxes 619  697 
Equity investments and securities (income)/loss, net 56  (43)
Net earnings 2,465  2,595 
Net earnings attributable to noncontrolling interests 134  177 
Net earnings attributable to PMI $ 2,331  $ 2,418 

Per share data (Note 6):
Basic earnings per share $ 1.50  $ 1.55 
Diluted earnings per share $ 1.50  $ 1.55 






See notes to condensed consolidated financial statements.
3

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
For the Three Months Ended March 31,
2022 2021
Net earnings $ 2,465  $ 2,595 
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $(31) in 2022 and $(85) in 2021
(194) 223 

Change in net loss and prior service cost:
Amortization of net losses, prior service costs and net transition costs, net of income taxes of $(13) in 2022 and $(18) in 2021
55  81 

Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $(20) in 2022 and $(14) in 2021
110  76 
(Gains) losses transferred to earnings, net of income taxes of $2 in 2022 and $0 in 2021
(9) 21 
Total other comprehensive earnings (losses) (38) 401 
Total comprehensive earnings
2,427  2,996 
Less comprehensive earnings attributable to:
Noncontrolling interests 279  143 
Comprehensive earnings attributable to PMI $ 2,148  $ 2,853 
















See notes to condensed consolidated financial statements.
4

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
 
March 31,
2022
December 31,
2021
ASSETS
Cash and cash equivalents $ 4,622  $ 4,496 
Trade receivables (less allowances of $32 in 2022 and $70 in 2021)
3,650  3,123 
Other receivables (less allowances of $36 in 2022 and $36 in 2021)
768  817 

Inventories:
Leaf tobacco 1,691  1,642 
Other raw materials 2,297  1,652 
Finished product 4,696  5,426 
8,684  8,720 
Other current assets 1,000  561 

Total current assets
18,724  17,717 

Property, plant and equipment, at cost
14,563  14,732 
Less: accumulated depreciation 8,559  8,564 
6,004  6,168 
Goodwill (Note 4) 6,632  6,680 
Other intangible assets, net (Note 4) 2,786  2,818 
Equity investments (Note 12) 4,312  4,463 
Deferred income taxes 694  895 
Other assets (less allowances of $21 in 2022 and $21 in 2021)
2,581  2,549 
TOTAL ASSETS $ 41,733  $ 41,290 









See notes to condensed consolidated financial statements.
Continued
5

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share data)
(Unaudited)
 
March 31,
2022
December 31,
2021
LIABILITIES
Short-term borrowings (Note 10) $ 2,441  $ 225 
Current portion of long-term debt (Note 10) 2,897  2,798 
Accounts payable 3,203  3,331 
Accrued liabilities:
Marketing and selling 678  811 
Taxes, except income taxes 5,618  6,324 
Employment costs 864  1,146 
Dividends payable 1,958  1,958 
Other 1,854  1,637 
Income taxes 904  1,025 
Total current liabilities 20,417  19,255 

Long-term debt (Note 10)
24,019  24,783 
Deferred income taxes 751  726 
Employment costs 2,880  2,968 
Income taxes and other liabilities 1,869  1,766 
Total liabilities 49,936  49,498 

Contingencies (Note 8)

STOCKHOLDERS’ (DEFICIT) EQUITY

Common stock, no par value
   (2,109,316,331 shares issued in 2022 and 2021)
—  — 
Additional paid-in capital 2,118  2,225 
Earnings reinvested in the business 33,468  33,082 
Accumulated other comprehensive losses (9,760) (9,577)
25,826  25,730 
Less: cost of repurchased stock
   (559,231,389 and 559,146,338 shares in 2022 and 2021, respectively)
35,924  35,836 
Total PMI stockholders’ deficit (10,098) (10,106)
Noncontrolling interests 1,895  1,898 
Total stockholders’ deficit (8,203) (8,208)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $ 41,733  $ 41,290 





See notes to condensed consolidated financial statements.
6

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
 
  For the Three Months Ended March 31,
  2022 2021
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings $ 2,465  $ 2,595 
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization 253  245 
Deferred income tax (benefit) provision (1) 33 
Asset impairment and exit costs, net of cash paid (Note 16) (28) (36)
Cash effects of changes, net of the effects from acquired companies:
Receivables, net (553) (427)
Inventories (232) 305 
Accounts payable 14  (67)
Accrued liabilities and other current assets (835) (2,108)
Income taxes (93) (91)
Pension plan contributions (34) (30)
Other 162  16 
Net cash provided by operating activities 1,118  435 
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures (229) (179)
Equity investments (20) — 
Net investment hedges 121  199 
Other (68) 35 
Net cash provided by (used in) investing activities (196) 55 
 















See notes to condensed consolidated financial statements.

Continued
7

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
 
  For the Three Months Ended March 31,
  2022 2021
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
Short-term borrowing activity by original maturity:
    Net issuances (repayments) - maturities of 90 days or less $ 1,916  $ (49)
    Issuances - maturities longer than 90 days 305  — 
Long-term debt repaid (496) (1,632)
Repurchases of common stock (209) — 
Dividends paid (1,952) (1,879)
Payments to noncontrolling interests and Other (Note 17)
(265) (89)
Net cash used in financing activities (701) (3,649)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (95) (220)
Cash, cash equivalents and restricted cash (1):
Increase (Decrease) 126  (3,379)
Balance at beginning of period 4,500  7,285 
Balance at end of period $ 4,626  $ 3,906 

(1) The amounts for cash, cash equivalents and restricted cash shown above include restricted cash of $4 million and $4 million as of March 31, 2022 and 2021, respectively, and $4 million and $5 million as of December 31, 2021 and 2020, respectively, which were included in other current assets in the condensed consolidated balance sheets.







See notes to condensed consolidated financial statements.
8

Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Three Months Ended March 31, 2022 and 2021
(in millions of dollars, except per share amounts)
(Unaudited)
  PMI Stockholders’ (Deficit) Equity    
  Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock
Noncontrolling
Interests
Total
Balances, January 1, 2021 $ —  $ 2,105  $ 31,638  $ (11,181) $ (35,129) $ 1,936  $ (10,631)
Net earnings 2,418  177  2,595 
Other comprehensive earnings (losses), net of income taxes 435  (34) 401 
Issuance of stock awards (25) 69  44 
Dividends declared ($1.20 per share)
(1,878) (1,878)
Payments to noncontrolling interests (105) (105)
Balances, March 31, 2021 $ —  $ 2,080  $ 32,178  $ (10,746) $ (35,060) $ 1,974  $ (9,574)
Balances, January 1, 2022 $ —  $ 2,225  $ 33,082  $ (9,577) $ (35,836) $ 1,898  $ (8,208)
Net earnings 2,331  134  2,465 
Other comprehensive earnings (losses), net of income taxes (12) (26) (38)
Issuance of stock awards (77) 111  34 
Dividends declared ($1.25 per share)
(1,945) (1,945)
Payments to noncontrolling interests (101) (101)
Common stock repurchased (199) (199)
Other (Note 17) (30) (171) (10) (211)
Balances, March 31, 2022 $ —  $ 2,118  $ 33,468  $ (9,760) $ (35,924) $ 1,895  $ (8,203)




See notes to condensed consolidated financial statements.
9

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
Note 1. Background and Basis of Presentation:

Background

Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United States of America), whose subsidiaries and affiliates and their licensees are primarily engaged in the manufacture and sale of cigarettes and reduced-risk products including heat-not-burn, vapor and oral nicotine products, in markets outside of the United States of America. Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries.

Reduced-risk products ("RRPs") is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization.

"Platform 1" is the term PMI uses to refer to PMI’s reduced-risk product that uses a precisely controlled heating device into which a specially designed and proprietary tobacco unit is inserted and heated to generate an aerosol.

Basis of Presentation

The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a consistent basis. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not necessarily indicative of results that may be expected for the entire year.

In the third quarter of 2021, PMI acquired Fertin Pharma A/S, Vectura Group plc. and OtiTopic, Inc. On March 31, 2022, PMI launched a new Wellness and Healthcare business consolidating these entities, Vectura Fertin Pharma. The operating results of this new business is reported in an Other category. For further details, see Note 7. Segment Reporting and Note 17. Acquisitions.

Certain prior years' amounts have been reclassified to conform with the current year's presentation. During the first quarter of 2022, one of Fertin Pharma's product lines was moved from the Other category to the European Union segment (reduced-risk product category). For further details, see Note 4. Goodwill and Other Intangible Assets, net. The change did not have a material impact on PMI's consolidated financial position, results of operations or cash flows in any of the periods presented.

These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report on Form 10-K for the year ended December 31, 2021.


10

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 2. Stock Plans:

In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Performance Incentive Plan (the “2017 Plan”). Under the 2017 Plan, PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity awards. Up to 25 million shares of PMI’s common stock may be issued under the 2017 Plan. At March 31, 2022, shares available for grant under the 2017 Plan were 12,644,751.

In May 2017, PMI’s shareholders also approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the “2017 Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-Employee Directors Plan. At March 31, 2022, shares available for grant under the plan were 914,413.

Restricted share unit (RSU) awards

During the three months ended March 31, 2022 and 2021, shares granted to eligible employees, the weighted-average grant date fair value per share and the recorded compensation expense related to RSU awards were as follows:
Number of
Shares
Granted
Weighted-Average Grant Date Fair Value Per RSU Award Granted Compensation Expense Related to RSU Awards
(in millions)
2022 1,551,050  $ 105.04  $ 39 
2021 1,972,770  $  81.86  $ 40 

As of March 31, 2022, PMI had $259 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58.

During the three months ended March 31, 2022, 1,447,664 RSU awards vested. The grant date fair value of all the vested awards was approximately $112 million. The total fair value of RSU awards that vested during the three months ended March 31, 2022 was approximately $159 million.

Performance share unit (PSU) awards

During the three months ended March 31, 2022 and 2021, PMI granted PSU awards to certain executives. The PSU awards require the achievement of certain performance metrics, which are predetermined at the time of grant, typically over a three-year performance cycle. The performance metrics for such PSU's granted during the three months ended March 31, 2022 consisted of PMI's Total Shareholder Return ("TSR") relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and a Sustainability Index, which consists of two drivers:

Product Sustainability (20% weight) measuring progress on PMI's efforts to maximize the benefits of smoke-free products, purposefully phase out cigarettes, seek net positive impact in wellness and healthcare, and reduce post-consumer waste; and

Operational Sustainability (10% weight) measuring progress on PMI's efforts to tackle climate change, preserve nature, improve the quality of life of people in its supply chain, and foster an empowered, and inclusive workplace.

The performance metrics for such PSU's granted during the three months ended March 31, 2021 consisted of PMI's TSR relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and PMI’s performance against specific measures of PMI’s transformation, defined as net revenues from PMI's RRPs and any other non-combustible products as a percentage of PMI's total net revenues in the last year of the performance cycle (30% weight).
11

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum percentage of 200. Each such vested PSU entitles the participant to one share of common stock. An aggregate weighted PSU performance factor of 100 will result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the accumulated dividends paid on common stock during the performance cycle for the number of shares earned.

During the three months ended March 31, 2022 and 2021, shares granted to eligible employee, the grant date fair value per share and the recorded compensation expense related to PSU awards were as follows:
Number of Shares Granted Grant Date 
Fair Value Subject to Other Performance Metrics
Grant Date 
Fair Value Subject to TSR Performance Metric
Compensation Expense Related to PSU Awards (in millions)
(Per Share) (Per Share)
2022 451,790  $ 105.07  $ 143.94  $ 21 
2021 574,410  $  81.86  $ 106.93  $ 12 

The grant date fair value of the PSU awards subject to the other performance metrics was determined by using the market price of PMI’s stock on the date of the grant. The grant date fair value of the PSU market based awards subject to the TSR performance metric was determined by using the Monte Carlo simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance metric:
2022 2021
Risk-free interest rate (a)
1.6  % 0.2  %
Expected volatility (b)
28.6  % 31.7  %
(a) Based on the U.S. Treasury yield curve.
(b) Determined using the observed historical volatility.

As of March 31, 2022, PMI had $76 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the performance cycle of the awards, or upon death, disability or reaching the age of 58.

During the three months ended March 31, 2022, 669,960 PSU awards vested. The grant date fair value of all the vested awards was approximately $54 million. The total fair value of PSU awards that vested during the three months ended March 31, 2022 was approximately $74 million.

Note 3. Benefit Plans:

Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed by local statutory requirements. In addition, PMI provides health care and other benefits to substantially all U.S. retired employees and certain non-U.S. retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans.

Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
  For the Three Months Ended March 31,
(in millions) 2022 2021
Net pension costs (income) $ (25) $ (1)
Net postemployment costs 27  28 
Net postretirement costs
Total pension and other employee benefit costs $ $ 28 
12

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Pension Plans

Components of Net Periodic Benefit Cost

Net periodic pension cost consisted of the following:
 
Pension (1)
  For the Three Months Ended March 31,
(in millions) 2022 2021
Service cost $ 60  $ 75 
Interest cost 20  13 
Expected return on plan assets (92) (95)
Amortization:
Net loss 48  80 
Prior service cost (1)
Net periodic pension cost $ 35  $ 74 
(1) Primarily non-U.S. based defined benefit retirement plans.

Employer Contributions
PMI makes, and plans to make, contributions, to the extent that they are tax deductible and meet specific funding requirements of its funded pension plans. Employer contributions of $34 million were made to the pension plans during the three months ended March 31, 2022. Currently, PMI anticipates making additional contributions during the remainder of 2022 of approximately $73 million to its pension plans, based on current tax and benefit laws. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on pension assets, or changes in interest and currency rates.

Note 4. Goodwill and Other Intangible Assets, net:

The movements in goodwill were as follows:
(in millions) European Union Eastern Europe Middle East & Africa South & Southeast Asia East Asia & Australia Americas Other Total
Balances, December 31, 2021 $ 1,397  $ 295  $ 79  $ 2,828  $ 539  $ 611  $ 931  $ 6,680 
Changes due to:
Currency (19) (8) (29) (7) 27  (20) (48)
Balances, March 31, 2022 $ 1,378  $ 287  $ 87  $ 2,799  $ 532  $ 638  $ 911  $ 6,632 

At March 31, 2022, goodwill primarily reflects PMI’s business combinations in Colombia, Greece, Indonesia, Mexico, Pakistan, the Philippines and Serbia, as well as the preliminary purchase price allocation of Fertin Pharma A/S and Vectura Group plc., which were acquired in September 2021.

As discussed in Note 1. Background and Basis of Presentation, during the first quarter of 2022, one of Fertin Pharma's product lines was moved from the Other category to the European Union segment. As a result, the December 31, 2021 opening goodwill balance in the table above included a reclassification of $24 million from the Other category to the European Union segment.

13

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Details of other intangible assets were as follows:
March 31, 2022 December 31, 2021
(in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net
Non-amortizable intangible assets $ 1,321  $ 1,321  $ 1,312  $ 1,312 
Amortizable intangible assets:
Trademarks 11 years 1,205  $ 656  549  1,201  $ 639  562 
Developed technology, including patents 12 years 855  82  773  859  63  796 
Other(1)
11 years 238  95  143  238  90  148 
Total other intangible assets $ 3,619  $ 833  $ 2,786  $ 3,610  $ 792  $ 2,818 
(1) Primarily includes distribution networks and customer relationships.

Non-amortizable intangible assets substantially consist of trademarks from PMI’s acquisitions in Indonesia and Mexico, as well as the preliminary purchase price allocation associated with PMI's business combinations in 2021 (primarily in-process research and development). The increase since December 31, 2021 was due to currency movements of $9 million.

The change in the accumulated amortization from December 31, 2021, was mainly due to the 2022 amortization of $38 million, and currency movements of $3 million.

Amortization expense for each of the next five years is estimated to be $150 million or less, assuming no additional transactions occur that require the amortization of intangible assets.



Note 5. Financial Instruments:

Overview

PMI operates in markets outside of the United States of America, with manufacturing and sales facilities in various locations around the world. PMI utilizes certain financial instruments to manage foreign currency and interest rate exposures. Derivative financial instruments are used by PMI principally to reduce exposures to market risks resulting from fluctuations in foreign currency exchange and interest rates by creating offsetting exposures. PMI is not a party to leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the consolidated balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Financial instruments qualifying for hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings.

PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, collectively referred to as foreign exchange contracts ("foreign exchange contracts"), and interest rate contracts to
14

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
mitigate its exposure to changes in exchange and interest rates from third-party and intercompany actual and forecasted transactions. Both foreign exchange contracts and interest rate contracts are collectively referred to as derivative contracts ("derivative contracts"). The primary currencies to which PMI is exposed include the Euro, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble and Swiss franc. At March 31, 2022, PMI had contracts with aggregate notional amounts of $25.8 billion of which $4.9 billion related to cash flow hedges, $7.9 billion related to hedges of net investments in foreign operations, $1.0 billion related to fair value hedges and $12.0 billion related to other derivatives that primarily offset currency exposures on intercompany financing.

The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021, were as follows:
  Derivative Assets Derivative Liabilities
  Fair Value Fair Value
At At At At
(in millions) Balance Sheet Classification March 31, 2022 December 31, 2021 Balance Sheet Classification March 31, 2022 December 31, 2021
Derivative contracts designated as hedging instruments Other current assets $ 291  $ 173  Other accrued liabilities $ 46  $ 34 
Other assets 63  22  Income taxes and other liabilities 182  190 
Derivative contracts not designated as hedging instruments 
Other current assets 
55  37  Other accrued liabilities 83  75 
Other assets —  —  Income taxes and other liabilities 14  — 
Total gross amount derivatives contracts presented in the condensed consolidated balance sheets   $ 409  $ 232    $ 325  $ 299 
Gross amounts not offset in the condensed consolidated balance sheets
Financial instruments (199) (126) (199) (126)
Cash collateral received/pledged (200) (93) (87) (151)
Net amount $ 10  $ 13  $ 39  $ 22 

PMI assesses the fair value of its foreign exchange contracts and interest rate contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates. PMI’s derivative contracts have been classified within Level 2 at March 31, 2022 and December 31, 2021.










15

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the three months ended March 31, 2022 and 2021, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows:

(pre-tax, in millions) For the Three Months Ended March 31,
Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings
Classification of Gain/(Loss)
on Derivatives
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings
2022 2021 2022 2021 2022 2021
Derivative contracts designated as hedging instruments:
Cash flow hedges $ 130  $ 90 
Net revenues $ 17  $ — 
Cost of sales —  — 
Marketing, administration and research costs (3) (18)
Interest expense, net (3) (3)
Fair value hedges Interest expense, net $ (37) $ — 
Net investment hedges (a)
105  318 
Interest expense, net (b)
33  42 
Derivative contracts not designated as hedging instruments: Interest expense, net 11 
Marketing, administration and research costs (c)
(1) 287 
Total $ 235  $ 408  $ 11  $ (21) $ $ 340 

(a) Amount of gains (losses) on hedges of net investments principally related to changes in exchange and interest rates between the Euro and U.S. dollar
(b) Represent the gains for amounts excluded from the effectiveness testing
(c) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates substantially offset the (losses) and gains generated by the underlying intercompany and third-party loans being hedged

Cash Flow Hedges

PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to certain forecasted transactions. Gains and losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses until the underlying hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of March 31, 2022, PMI has hedged forecasted transactions for periods not exceeding the next twenty-one months with the exception of one derivative contract that expires in May 2024. The impact of these hedges is primarily included in operating cash flows on PMI’s condensed consolidated statements of cash flows.
16

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Fair Value Hedges

PMI has entered into fixed-to-floating interest rate contracts, designated as fair value hedges to minimize exposure to changes in the fair value of fixed rate U.S. dollar-denominated debt that results from fluctuations in benchmark interest rates. For derivative contracts that are designated and qualify as fair value hedges the gain or loss on the derivative, as well as the offsetting gain or loss on the hedged items attributable to the hedged risk, is recognized in current earnings. The carrying amount of the debt hedged, which includes the cumulative adjustment for fair value gains/losses, as of March 31, 2022 was $957 million, and is recorded in long-term debt in the condensed consolidated balance sheets. The cumulative amount of fair value gains/(losses) included in the carrying amount of the debt hedged was $(36) million as of March 31, 2022.

Hedges of Net Investments in Foreign Operations

PMI designates derivative contracts and certain foreign currency denominated debt instruments as net investment hedges, primarily of its Euro net assets. For the three months ended March 31, 2022 and 2021, the amount of pre-tax gain/(loss) related to these debt instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $66 million and $181 million, respectively. The premiums paid for, and settlements of, net investment hedges are included in investing cash flows on PMI’s condensed consolidated statements of cash flows.

Other Derivatives

PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain subsidiaries, and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses) relating to these contracts are reported in PMI’s condensed consolidated statements of earnings.
Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses

Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows:
(in millions) For the Three Months Ended March 31,
  2022 2021
Gain/(loss) as of January 1, $ $ (85)
Derivative (gains)/losses transferred to earnings (9) 21 
Change in fair value 110  76 
Gain/(loss) as of March 31, $ 105  $ 12 

At March 31, 2022, PMI expects $76 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings impact of the respective hedged transactions.
Contingent Features
PMI’s derivative instruments do not contain contingent features.
Credit Exposure and Credit Risk
PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as counterparties.
17

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Investments

A PMI investment, which is comprised primarily of money market funds, has been classified within Level 1 and had a fair value of $82 million at March 31, 2022. For the three months ended March 31, 2022 the unrealized pre-tax gains on these investments were immaterial.


Note 6. Earnings Per Share:
Basic and diluted earnings per share (“EPS”) were calculated using the following:
(in millions) For the Three Months Ended March 31,
  2022 2021
Net earnings attributable to PMI $ 2,331  $ 2,418 
Less distributed and undistributed earnings attributable to share-based payment awards
Net earnings for basic and diluted EPS $ 2,324  $ 2,411 
Weighted-average shares for basic EPS 1,550  1,558 
Plus contingently issuable performance stock units (PSUs)
Weighted-average shares for diluted EPS 1,552  1,560 

Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are included in PMI’s earnings per share calculation pursuant to the two-class method.

For the 2022 and 2021 computations, there were no antidilutive stock awards.

Note 7. Segment Reporting:

PMI’s subsidiaries and affiliates are primarily engaged in the manufacture and sale of cigarettes and RRPs, including heat-not-burn, vapor and oral nicotine products, in markets outside of the United States of America. PMI's segments are generally organized by geographic region and managed by segment managers who are responsible for the operating and financial results of the regions inclusive of combustible and reduced-risk product categories sold in the region. PMI currently has six geographical segments: the European Union; Eastern Europe; Middle East & Africa; South & Southeast Asia; East Asia & Australia; and Americas; as well as an Other category. Other consists of the operating results of PMI's new Wellness and Healthcare business, Vectura Fertin Pharma. For further details on these acquisitions, see Note 17. Acquisitions. PMI records net revenues and operating income to its geographical segments based upon the geographic area in which the customer resides.

PMI’s chief operating decision maker evaluates geographical segment performance and allocates resources based on regional operating income, which includes results from all product categories sold in each region. Business operations in the Other category are managed and evaluated separately.

PMI disaggregates its net revenue from contracts with customers by both geographic location and product category for each of PMI's six geographical segments. For the new Wellness and Healthcare business discussed above, net revenues from contracts with customers are included in the Other category. PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.

18

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Segment data were as follows:
(in millions) For the Three Months Ended March 31,
2022 2021
Net revenues:
European Union $ 3,012  $ 2,909 
Eastern Europe 726  796 
Middle East & Africa 991  801 
South & Southeast Asia 1,123  1,173 
East Asia & Australia 1,404  1,472 
Americas 424  434 
Other 66  — 
Net revenues $ 7,746  $ 7,585 
Operating income (loss):
European Union $ 1,527  $ 1,490 
Eastern Europe 144  261 
Middle East & Africa 521  335 
South & Southeast Asia 445  529 
East Asia & Australia 571  695 
Americas 121  134 
Other (31) — 
Operating income $ 3,298  $ 3,444 

Items affecting the comparability of results from operations were as follows:

Asset impairment and exit costs - See Note 16. Asset Impairment and Exit Costs for details of the $48 million pre-tax charge and a breakdown of these costs by segment for the three months ended March 31, 2021.
Charges related to the war in Ukraine - See Note 18. War in Ukraine for details of the $42 million pre-tax charges in the Eastern Europe segment for the three months ended March 31, 2022.
19

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

PMI's net revenues by product category were as follows:
(in millions) For the Three Months Ended March 31,
2022 2021
Net revenues:
Combustible products:
European Union $ 1,810  $ 1,950 
Eastern Europe 456  492 
Middle East & Africa 929  780 
South & Southeast Asia 1,118  1,171 
East Asia & Australia 601  648 
Americas 416  422 
Total combustible products $ 5,330  $ 5,463 
Reduced-risk products:
European Union $ 1,202  $ 959 
Eastern Europe 270  304 
Middle East & Africa 62  21 
South & Southeast Asia
East Asia & Australia 803  824 
Americas 12 
Total reduced-risk products $ 2,350  $ 2,122 
Other:
Other $ 66  $ — 
Total PMI net revenues $ 7,746  $ 7,585 
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.

Net revenues related to combustible products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and other tobacco products combined. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and cigarillos, and do not include reduced-risk products.

Net revenues related to reduced-risk products refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's heated tobacco units, heat-not-burn devices and related accessories, and other nicotine-containing products, which primarily include PMI's e-vapor and oral nicotine products.

Net revenues in the Other category primarily consist of operating revenues generated from the sale of inhaled therapeutics, and oral and intra-oral delivery systems that are included in the operating results of PMI's new Wellness and Healthcare business, Vectura Fertin Pharma.


20

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 8. Contingencies:
Tobacco-Related Litigation
Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend, as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for PMI.
It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending tobacco-related litigation could encourage the commencement of additional litigation.
Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Brazil, Canada and Nigeria, range into the billions of U.S. dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. Much of the tobacco-related litigation is in its early stages, and litigation is subject to uncertainty. However, as discussed below, we have to date been largely successful in defending tobacco-related litigation.
We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 8. Contingencies, while it is reasonably possible that an unfavorable outcome in a case may occur, after assessing the information available to it (i) management has not concluded that it is probable that a loss has been incurred in any of the pending tobacco-related cases; (ii) management is unable to estimate the possible loss or range of loss for any of the pending tobacco-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for unfavorable outcomes in these cases, if any. Legal defense costs are expensed as incurred.
It is possible that our consolidated results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended. However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so.    
CCAA Proceedings and Stay of Tobacco-Related Cases Pending in Canada
As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson & Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA order made by the Ontario Superior Court on March 22, 2019 authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course after the CCAA filing, including obligations to employees, vendors, and suppliers. As further described in Item 8, Note 20. Deconsolidation of RBH of PMI's Annual Report on Form 10-K for the year ended December 31, 2021, RBH's financial results have been deconsolidated from our consolidated financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30, 2022 of all tobacco-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria), namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented below under the caption “Stayed Litigation — Canada.” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation, it is anticipated that the court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau and the Blais cases so long as the comprehensive stay of all tobacco-related litigation in Canada remains in effect and that the time period to file the application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases were incorrect, the CCAA proceedings will provide a forum for
21

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
RBH to seek resolution through a plan of arrangement or compromise of all tobacco-related litigation pending in Canada. It is not possible to predict the resolution of the underlying legal proceedings or the length of the CCAA process.

Stayed Litigation — Canada

Smoking and Health Litigation — Canada

In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in November 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants. The plaintiffs, an anti-smoking organization and an individual smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain smoking-related diseases. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and found that the class members’ compensatory damages totaled approximately CAD 15.5 billion, including pre-judgment interest (approximately $12.2 billion). The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion, including pre-judgment interest (approximately $2.4 billion)). In addition, the trial court awarded CAD 90,000 (approximately $70,800) in punitive damages, allocating CAD 30,000 (approximately $23,600) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $178 million) to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco Canada Ltd. to furnish security totaling CAD 758 million (approximately $596 million) in installments through June 2017. JTI Macdonald Corp. was not required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal.

On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion including interest (approximately $10.6 billion) due to the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH (approximately CAD 2.7 billion, including pre-judgment interest (approximately $2.1 billion)). The Court of Appeal upheld the trial court’s findings that defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais case, approximately CAD 1.1 billion (approximately $865 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD 257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax, as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment.

In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants.  The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $103 million) in punitive damages, allocating CAD 46 million (approximately $36 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD 57 million including interest (approximately $45 million) to RBH. See the Blais description above and Item 8, Note 20. Deconsolidation of RBH in PMI's Annual Report on Form 10-K for the year ended December 31, 2021 for further detail concerning the security order pertaining to both Létourneau and Blais cases and the impact of the decision on PMI’s financial statements.
22

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on several grounds including the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking; (ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to all class members given the individual differences between class members.
In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada, filed June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products.
In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada, filed July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, emphysema, heart disease, or cancer, as well as restitution of profits.
In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia, Canada, filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products.
In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have not been properly served with the complaint.
In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed.

In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim.

In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised
23

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as restitution of profits.

Health Care Cost Recovery Litigation — Canada
In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting from a “tobacco related wrong.”
In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of Justice, Toronto, Canada, filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, St. Johns, Canada, filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec, Canada, filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench Alberta, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges, Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada, filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench, Judicial Centre of Saskatchewan, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws enacted in several other Canadian
24

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada, filed September 10, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”

In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Nova Scotia, Canada, filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
__________
The table below lists the number of tobacco-related cases pertaining to combustible products pending against us and/or our subsidiaries or indemnitees as of March 31, 2022, and March 31, 2021:¹

Type of Case Number of Cases Pending as of March 31, 2022 Number of Cases Pending as of March 31, 2021
Individual Smoking and Health Cases 41 43
Smoking and Health Class Actions 9 9
Health Care Cost Recovery Actions 17 17
Label-Related Class Actions
Individual Label-Related Cases 5 5
Public Civil Actions 1 2

Since 1995, when the first tobacco-related litigation was filed against a PMI entity, 524 Smoking and Health, Label-Related, Health Care Cost Recovery, and Public Civil Actions in which we and/or one of our subsidiaries and/or indemnitees were a defendant have been terminated in our favor. Fourteen cases have had decisions in favor of plaintiffs. Ten of these cases have subsequently reached final resolution in our favor and four remain on appeal.






______
¹ Includes cases pending in Canada.











25

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

The table below lists the verdict and significant post-trial developments in the four pending cases where a verdict was returned in favor of the plaintiff:
Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
May 27, 2015    Canada/Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais
   Class Action   
On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Blais class on liability and found the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $12.2 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion including pre-judgment interest (approximately $2.4 billion)). The trial court awarded CAD 90,000 (approximately $70,800) in punitive damages, allocating CAD 30,000 (approximately $23,600) to our subsidiary. The trial court ordered defendants to pay CAD 1 billion (approximately $786 million) of the compensatory damage award, CAD 200 million (approximately $157 million) of which is our subsidiary’s portion, into a trust within 60 days.
  
In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.)
26

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
May 27, 2015    Canada/Cecilia Létourneau
   Class Action   
On May 27, 2015, the Superior Court of the District of Montreal, Province of Quebec ruled in favor of the Létourneau class on liability and awarded a total of CAD 131 million (approximately $103 million) in punitive damages, allocating CAD 46 million (approximately $36 million) to RBH. The trial court ordered defendants to pay the full punitive damage award into a trust within 60 days. The court did not order the payment of compensatory damages.
  
In June 2015, RBH commenced the appellate process with the Court of Appeal of Quebec. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court's decision. (See “Stayed Litigation — Canada” for further detail.)
Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
August 5, 2016 Argentina/Hugo Lespada Individual Action
On August 5, 2016, the Civil Court No. 14 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded him ARS 110,000 (approximately $963), plus interest, in compensatory and moral damages. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes.
On August 23, 2016, our subsidiary filed its notice of appeal. On October 31, 2017, the Civil and Commercial Court of Appeals of Mar del Plata ruled that plaintiff's claim was barred by the statute of limitations and it reversed the trial court's decision. On May 17, 2021 plaintiff filed a federal extraordinary appeal. On November 1, 2021, the Supreme Court of the Province of Buenos Aires dismissed plaintiff's federal extraordinary appeal. On November 10, 2021, plaintiff filed a direct appeal before the Federal Supreme Court.
27

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Date    Location of
Court/Name of
Plaintiff
   Type of
Case
   Verdict    Post-Trial
Developments
June 17, 2021 Argentina/Claudia Milano Individual Action
On June 17, 2021, the Civil Court No. 9 - Mar del Plata, issued a verdict in favor of plaintiff, an individual smoker, and awarded her smoking cessation treatments, ARS 150,000 (approximately $1,314), in compensatory and moral damages, and ARS 4,000,000 (approximately $35,028) in punitive damages, plus interest and costs. The trial court found that our subsidiary failed to warn plaintiff of the risk of becoming addicted to cigarettes.
On July 2, 2021, our subsidiary filed its notice of appeal. In addition, plaintiff filed an appeal challenging the dismissal of the claim for psychological damages. As required by local law, our subsidiary deposited the damages awarded, plus interest and costs, in total ARS 6,114,428 (approximately $53,544), into a court escrow account. Our subsidiary challenged the amount determined by the court. The Mar del Plata Court of Appeals granted our subsidiary's challenge to the escrow amount determined by the trial court. As a result, on December 16, 2021, ARS 893,428 (approximately $7,823) was returned to our subsidiary. If our subsidiary ultimately prevails on appeal, the remaining deposited amounts will be returned to our subsidiary.
Pending claims related to tobacco products generally fall within the following categories:
Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause, assumption of the risk, contributory negligence, and statute of limitations.
As of March 31, 2022, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows:

41 cases brought by individual plaintiffs in Argentina (30), Brazil (2), Canada (2), Chile (3), the Philippines (1), Turkey (1) and Scotland (1), as well as 1 case brought by an individual plaintiff in the United States District Court for the District of Oregon in May 2021 (See information regarding the provisions of the 2008 Share Distribution Agreement between PMI and Altria that provide for indemnities to PMI for certain liabilities concerning tobacco products under the caption "Tobacco-Related Litigation" described above), compared with 43 such cases on March 31, 2021; and
9 cases brought on behalf of classes of individual plaintiffs, compared with 9 such cases on March 31, 2021.

The class actions pending in Canada are described above under the caption “Smoking and Health Litigation — Canada.

Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under statutes governing
28

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim, adequate remedy at law, “unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of cigarettes), and statute of limitations.
As of March 31, 2022, there were 17 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Brazil (1), Canada (10), Korea (1) and Nigeria (5), compared with 17 such cases on March 31, 2021.

The health care cost recovery actions pending in Canada are described above under the caption “Health Care Cost Recovery Litigation — Canada.
In the health care cost recovery case in Brazil, The Attorney General of Brazil v. Souza Cruz Ltda., et al., Federal Trial Court, Porto Alegre, Rio Grande do Sul, Brazil, filed May 21, 2019, we, our subsidiaries, and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases in certain prior years, payment of anticipated costs of treating future alleged smoking-related diseases, and moral damages. Defendants filed answers to the complaint in May 2020.
In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of challenging the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served.
In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al., High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants. Plaintiffs seek reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served.
In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court of Ogun State, Abeokuta, Nigeria, filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our objections to the court's jurisdiction. We have appealed. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.

In the health care cost recovery case in Korea, the National Health Insurance Service v. KT&G, et. al., filed April 14, 2014, our subsidiary and other Korean manufacturers are defendants. Plaintiff alleges that defendants concealed the health hazards of smoking, marketed to youth, added ingredients to make their products more harmful and addictive, and misled consumers into believing that Lights cigarettes are safer than regular cigarettes. The National Health Insurance Service seeks to recover
29

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
damages allegedly incurred in treating 3,484 patients with small cell lung cancer, squamous cell lung cancer, and squamous cell laryngeal cancer from 2003 to 2012. The trial court dismissed the case in its entirety on November 20, 2020. Plaintiff appealed.

Label-Related Cases: These cases, now brought only by individual plaintiffs, allege that the use of the descriptor “Lights” or other alleged misrepresentations or omissions of labeling information constitute fraudulent and misleading conduct. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including misrepresentation, deception, and breach of consumer protection laws. Plaintiffs seek various forms of relief including restitution, injunctive relief, and compensatory and other damages. Defenses raised include lack of causation, lack of reliance, assumption of the risk, and statute of limitations.

As of March 31, 2022, there were 5 label-related cases brought by individual plaintiffs in Italy (1) and Chile (4) pending against our subsidiaries, compared with 5 such cases on March 31, 2021.

Public Civil Actions: Claims have been filed either by an individual, or a public or private entity, seeking to protect collective or individual rights, such as the right to health, the right to information or the right to safety. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including product defect, concealment, and misrepresentation. Plaintiffs in these cases seek various forms of relief including injunctive relief such as banning cigarettes, descriptors, smoking in certain places and advertising, as well as implementing communication campaigns and reimbursement of medical expenses incurred by public or private institutions.

As of March 31, 2022, there was 1 public civil action pending against our subsidiary in Venezuela (1), compared with 2 such cases on March 31, 2021.

In a public civil action in Venezuela, Federation of Consumers and Users Associations (“FEVACU”), et al. v. National Assembly of Venezuela and the Venezuelan Ministry of Health, Constitutional Chamber of the Venezuelan Supreme Court, filed April 29, 2008, we were not named as a defendant, but the plaintiffs published a notice pursuant to court order, notifying all interested parties to appear in the case. In January 2009, our subsidiary appeared in the case in response to this notice. The plaintiffs purport to represent the right to health of the citizens of Venezuela and claim that the government failed to protect adequately its citizens' right to health. The claim asks the court to order the government to enact stricter regulations on the manufacture and sale of tobacco products. In addition, the plaintiffs ask the court to order companies involved in the tobacco industry to allocate a percentage of their “sales or benefits” to establish a fund to pay for the health care costs of treating smoking-related diseases. In October 2008, the court ruled that plaintiffs have standing to file the claim and that the claim meets the threshold admissibility requirements. In December 2012, the court admitted our subsidiary and BAT's subsidiary as interested third parties. In February 2013, our subsidiary answered the complaint.

Reduced-Risk Products

In Colombia, an individual filed a purported class action, Ana Ferrero Rebolledo v. Philip Morris Colombia S.A., et al., in April 2019 against our subsidiaries with the Civil Court of Bogota related to the marketing of our Platform 1 product. Plaintiff alleged that our subsidiaries advertise the product in contravention of law and in a manner that misleads consumers by portraying the product in a positive light, and further asserts that the Platform 1 vapor contains many toxic compounds, creates a high level of dependence, and has damaging second-hand effects. Plaintiff sought injunctive relief and damages on her behalf and on a behalf of two classes (class 1 - all Platform 1 consumers in Colombia who seek damages for the purchase price of the product and personal injuries related to the alleged addiction, and class 2 - all residents of the neighborhood where the advertising allegedly took place who seek damages for exposure to the alleged illegal advertising). Our subsidiaries answered the complaint in January 2020, and in February 2020, plaintiff filed an amended complaint. The amended complaint modifies the relief sought on behalf of the named plaintiff and on behalf of a single class (all consumers of Platform 1 products in Colombia who seek damages for the product purchase price and personal injuries related to the use of an allegedly harmful product). In June 2021, our subsidiaries answered the amended complaint.

30

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Litigation

The Department of Special Investigations of the government of Thailand ("DSI") conducted an investigation into alleged underpayment by our subsidiary, Philip Morris (Thailand) Limited ("PM Thailand"), of customs duties and excise taxes relating to imports from the Philippines covering the period 2003-2007. On January 18, 2016, the Public Prosecutor filed charges against our subsidiary and seven former and current employees in the Bangkok Criminal Court alleging that PM Thailand and the individual defendants jointly and with the intention to defraud the Thai government, under-declared import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries of cigarettes from the Philippines during the period of July 2003 to June 2006. The government is seeking a fine of approximately THB 80.8 billion (approximately $2.4 billion). In May 2017, Thailand enacted a new customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and other Thai governmental agencies. Trial in the case began in November 2017 and concluded in September 2019. In November 2019, the trial court found our subsidiary guilty of under-declaration of the prices and imposed a fine of approximately THB 1.2 billion (approximately $35 million). The trial court dismissed all charges against the individual defendants. In December 2019, as required by the Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal of charges against the individual defendants and the amount of the fine imposed. If our subsidiary ultimately prevails on appeal, then Thailand will be required to return this payment to our subsidiary. The appellate court is scheduled to issue its decision on the appeals on June 1, 2022.

The DSI also conducted an investigation into alleged underpayment by PM Thailand of customs duties and excise taxes relating to imports from Indonesia covering the period 2000-2003. On January 26, 2017, the Public Prosecutor filed charges against PM Thailand and its former Thai employee in the Bangkok Criminal Court alleging that PM Thailand and its former employee jointly and with the intention to defraud the Thai government under-declared import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries during the period from January 2002 to July 2003. The government is seeking a fine of approximately THB 19.8 billion (approximately $582 million). In May 2017, Thailand enacted a new customs act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and a Thai court. Trial in the case began in November 2018 and concluded in December 2019. In March 2020, the trial court found our subsidiary guilty of under-declaration of the prices and imposed a fine of approximately THB 130 million (approximately $4 million). The trial court dismissed all charges against the individual defendant. In April 2020, as required by Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal of charges against the individual defendant and the amount of the fine imposed. If our subsidiary ultimately prevails on appeal, then Thailand will be required to return this payment to our subsidiary. The appellate court is scheduled to issue its decision on the appeals on August 30, 2022.

The South Korean Board of Audit and Inspection (“BAI”) conducted an audit of certain Korean government agencies and the tobacco industry into whether inventory movements ahead of the January 1, 2015 increase of cigarette-related taxes by tobacco companies, including Philip Morris Korea Inc. ("PM Korea"), our South Korean subsidiary, were in compliance with South Korean tax laws.  In November 2016, the tax authorities completed their audit and assessed allegedly underpaid taxes and penalties.  In order to avoid nonpayment financial costs, PM Korea paid approximately KRW 272 billion (approximately $219 million), of which KRW 100 billion (approximately $80 million) was paid in 2016 and KRW 172 billion (approximately $138 million) was paid in the first quarter of 2017.  These paid amounts are included in other assets in the condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment.  PM Korea appealed the assessments. In January 2020, a trial court ruled that PM Korea did not underpay taxes in the amount of approximately KRW 218 billion (approximately $175 million). The tax authorities appealed this decision to the appellate court. In September 2020, the appellate court upheld the trial court's decision. The tax authorities have appealed to the Supreme Court of South Korea. In June 2020, another trial court ruled that PM Korea did not underpay approximately KRW 54 billion (approximately $43 million) of alleged underpayments. The government agencies appealed this decision. In January 2021, the appellate court upheld the trial court's decision. The government agencies appealed to the Supreme Court of South Korea. If the tax authorities and government agencies ultimately lose, then they would be required to return the paid amounts to PM Korea.

31

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

The Saudi Arabia Customs General Authority issued its assessments requiring our distributors to pay additional customs duties in the amount of approximately 1.5 billion Saudi Riyal, or approximately $396 million, in relation to the fees paid by these distributors under their agreements with our subsidiary for exclusive rights to distribute our products in Saudi Arabia. In order to challenge these assessments, the distributors posted bank guarantees. To enable the distributors' challenge, our subsidiary agreed with the banks to bear a portion of the amount the authority may draw on the bank guarantees. In September and October 2020, respectively, the distributors lost their challenges of the assessments. Both distributors appealed, and in June 2021, the Customs Appeal Committee in Riyadh notified the distributors of its decisions to largely reject their appeals. On the basis of the above-mentioned decisions, in June 2021, PMI recorded a pre-tax charge of $246 million in relation to the period of 2014 through 2020 in line with existing and contemplated arrangements with the distributors. The estimated amounts for 2021 and 2022 are immaterial. In accordance with U.S. GAAP, the charge was recorded as a reduction in net revenues on the consolidated statements of earnings for the three months and six months ended June 30, 2021. Despite the unfavorable decisions, our subsidiary believes that customs duties paid in Saudi Arabia were in compliance with the applicable law and the WTO Customs Valuation Agreement.

A putative shareholder class action lawsuit, In re Philip Morris International Inc. Securities Litigation, is pending in the United States District Court for the Southern District of New York, purportedly on behalf of purchasers of Philip Morris International Inc. stock between July 26, 2016 and April 18, 2018.  The lawsuit names Philip Morris International Inc. and certain officers and employees as defendants and includes allegations that the defendants made false and/or misleading statements and/or failed to disclose information about PMI’s business, operations, financial condition, and prospects, related to product sales of, and alleged irregularities in clinical studies of, PMI’s Platform 1 product.  The lawsuit seeks various forms of relief, including damages. In November 2018, the court consolidated three putative shareholder class action lawsuits with similar allegations previously filed in the Southern District of New York (namely, City of Westland Police and Fire Retirement System v. Philip Morris International Inc., et al., Greater Pennsylvania Carpenters’ Pension Fund v. Philip Morris International Inc., et al., and Gilchrist v. Philip Morris International Inc., et al.) into these proceedings. A putative shareholder class action lawsuit, Rubenstahl v. Philip Morris International Inc., et al., that had been previously filed in December 2017 in the United States District Court for the District of New Jersey, was voluntarily dismissed by the plaintiff due to similar allegations in these proceedings. On February 4, 2020, the court granted defendants’ motion in its entirety, dismissing all but one of the plaintiffs’ claims with prejudice.  The court noted that one of plaintiffs’ claims (allegations relating to four non-clinical studies of PMI’s Platform 1 product) did not state a viable claim but allowed plaintiffs to replead that claim by March 3, 2020. On February 18, 2020, the plaintiffs filed a motion for reconsideration of the court's February 4th decision; this motion was denied on September 21, 2020. On September 28, 2020, plaintiffs filed an amended complaint seeking to replead allegations relating to four non-clinical studies of PMI's Platform 1 product. On September 10, 2021, the court granted defendant's motion to dismiss plaintiffs' amended complaint in its entirety. Plaintiffs have filed an appeal with the U.S. Court of Appeal for the Second Circuit. We believe that this lawsuit is without merit and will continue to defend it vigorously.

In April 2020, affiliates of British American Tobacco plc (“BAT”) commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Altria Client Services LLC, et al.,  in the federal court in the Eastern District of Virginia, where PMI's subsidiary, Philip Morris Products S.A., as well as Altria Group, Inc.'s subsidiaries, are defendants. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 blade products in the United States.  In April 2020, BAT affiliates filed a complaint against PMI, Philip Morris Products S.A., Altria Group, Inc., and its subsidiaries before the International Trade Commission ("ITC"). Plaintiffs seek an order to prevent the importation of Platform 1 products into the United States. The ITC evidentiary hearing closed on February 1, 2021. On May 14, 2021, the administrative law judge issued an Initial and Recommended Determination ("ID/RD") finding that the Platform 1 blade products infringe two of the three patents asserted by Plaintiffs, recommending that the ITC issue a Limited Exclusion order against infringing products, and recommending against a cease-and-desist, as well as recommending against a bond pending Presidential review of the ITC's Final Determination ("FD"). Defendants and Plaintiffs filed separate Petitions for Review with the ITC of the ID on May 28, 2021; on July 27, 2021, the ITC granted each of the petitions in part, deciding to review certain issues in the ID. Plaintiffs and Defendants also submitted brief statements of the public interest factors in issue to the ITC on June 15, 2021. On September 29, 2021, the ITC issued its FD finding a violation of section 337 of the U.S. Tariff Act and issued (a) a limited exclusion order against Philip Morris Products S.A., prohibiting, inter alia, the importation of Platform 1 product and infringing components; and (b) a cease-and-desist order against Altria Client Services, LLC and its affiliate prohibiting, inter alia, sales of imported Platform 1 products. The ITC predicated the orders on its finding that Platform 1 blade products infringe two patents owned by a BAT affiliate. The ITC also found that Platform 1 blade products do not infringe a third patent owned by a BAT affiliate. The ITC further held that there were insufficient concerns over public interest to prevent the issuance of remedial orders. Following the Presidential Review period, the orders became effective and Defendants filed a petition for review of the FD with the U.S. Court of Appeals for the Federal Circuit. Defendants also filed motions in the ITC and Federal Circuit for a stay of the orders
32

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
pending disposition of the appeal; the ITC denied the motion on January 20, 2022 and the Federal Circuit denied the motion on January 25, 2022. We estimate that an adverse ruling is probable due to our inability to import the products and components impacted by the ITC's FD with immaterial financial impact. In the Eastern District of Virginia case, the defendants also counterclaimed that BAT infringed their patents relating to certain e-vapor products, seeking damages for, and injunctive relief against, the commercialization of these products by BAT; defendants' claims against BAT are set for trial beginning the week of June 6, 2022. Upon petition of Philip Morris Products S.A., the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office has instituted review of certain claims pertaining to four of the six patents asserted by BAT affiliates in both proceedings. On January 11, 2022, PTAB issued its final decision on one of the two patents underlying the ITC's FD, invalidating all challenged claims of BAT's patent. On March 30, 2022, PTAB issued its final decision on the second of the two patents underlying the ITC's FD, finding the challenged claims patentable. The parties may appeal PTAB results to the U.S. Court of Appeals for the Federal Circuit.

In April 2020, BAT’s affiliate commenced patent infringement proceedings, Nicoventures Trading Limited v. PM GmbH, et al., against PMI’s German subsidiary, Philip Morris GmbH, and Philip Morris Products S.A., in the Regional Court in Munich, Germany. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 blade products in Germany. In June 2021, the court stayed the proceeding in respect of one of the two patents asserted by BAT’s Affiliate.

In September 2020, BAT’s affiliates commenced patent infringement and unfair competition proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Products S.A., et al., against Philip Morris Products S.A. and PMI’s Italian subsidiaries, Philip Morris Manufacturing & Technology Bologna S.p.A. and Philip Morris Italia S.r.l., in the Court of Milan, Italy. Plaintiffs seek damages, as well as injunctive relief against the manufacture in Italy of the Platform 1 blade heated tobacco units allegedly infringing the asserted patents and the commercialization of the Platform 1 blade products in Italy. As part of this proceeding, in October 2020, BAT’s affiliates filed a request based on one of the two asserted patents seeking preliminary injunctive relief against the manufacture and commercialization of the Platform 1 blade products in Italy.

In October 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Japan, Limited, et al., against PMI’s Japanese subsidiary, Philip Morris Japan Limited, and a third-party distributor in the Tokyo District Court. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 blade products in Japan.

In November 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Romania SRL, et al., against PMI’s Romanian subsidiaries, Philip Morris Romania S.R.L. and Philip Morris Trading S.R.L., and a third-party distributor in the Court of Law of Bucharest, Civil Registry. Plaintiffs seek damages and preliminary and permanent injunctive relief against the manufacture and commercialization of the Platform 1 blade products in Romania. In February 2021, the court dismissed plaintiffs’ request for a preliminary injunction. In April 2021, the appellate court denied plaintiffs' appeal, confirming the dismissal of plaintiffs' request for preliminary injunction. Plaintiffs' proceeding requesting damages and a permanent injunction remains pending before the Court of Law of Bucharest, Civil Registry. In an October 14, 2021 hearing, the court stayed the proceeding.

In March 2021, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Korea, Co., Ltd., against PM Korea in the Seoul Central District Court. Plaintiffs seek damages and injunctive relief against the commercialization of the Platform 1 blade heated tobacco units in South Korea.

In July, 2021, Philip Morris Products, S.A. filed a claim at the High Court of Justice of England and Wales against BAT affiliates Nicoventures Trading Limited and British American Tobacco (Investments) Limited seeking revocation of the UK parts of two BAT European patents. In January 2022, the court ordered that the trial of the action will be in September 2022, and the trial has subsequently been set to start on September 20, 2022. In March, the BAT affiliates stated that they would consent to revocation of one of the patents and filed an application with the court to bring a counterclaim against Philip Morris Products S.A. and Philip Morris Limited seeking from the court a declaration that the remaining BAT affiliate patent is infringed by Platform 1 induction products, as well as damages and injunctive relief against the commercialization of the Platform 1 induction products in the U.K.

Other patent challenges by both parties are pending in various jurisdictions.

We believe that the foregoing proceedings by the affiliates of BAT are without merit and will defend them vigorously.

We are also involved in additional litigation arising in the ordinary course of our business. While the outcomes of these proceedings are uncertain, management does not expect that the ultimate outcomes of other litigation, including any reasonably possible losses in excess of current accruals, will have a material adverse effect on our consolidated results of operations, cash flows or financial position.
33

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Third-Party Guarantees

On October 17, 2020, Medicago Inc., an equity method investee of Philip Morris Investments B.V. (“PMIBV”), a PMI subsidiary, entered into a contribution agreement with the Canadian government (the “Contribution Agreement”) whereby the Canadian government agreed to contribute up to CAD 173 million (approximately $131 million on the date of signing) to Medicago Inc., to support its on-going COVID-19 vaccine development and clinical trials, and for the construction of its Quebec City manufacturing facility (the “Project”). On March 31, 2022, the Contribution Agreement was amended (the “Contribution Agreement Amendment”) to reflect an additional contribution from the Canadian government up to CAD 27 million (approximately $22 million on the date of signing) to Medicago Inc. for the construction of its Quebec City manufacturing facility. PMIBV and the majority shareholder of Medicago Inc. are also parties to the Contribution Agreement and the Contribution Agreement Amendment as guarantors of Medicago Inc.’s obligations thereunder on a joint and several basis (“Co-Guarantors”). The Co-Guarantors agreed to repay amounts contributed by the Canadian government plus interest, if Medicago Inc. fails to do so, and could be responsible for the costs of other Medicago’s obligations (such as the achievement of specific milestones of the Project). The maximum amount of these obligations is currently non-estimable. As of March 31, 2022, PMI has determined that these guarantees did not have a material impact on its condensed consolidated financial statements.

In connection with the Contribution Agreement, PMIBV and the majority shareholder of Medicago Inc. entered into a guarantors’ agreement that apportions Co-Guarantors’ obligations and limits those of PMIBV to its share of holdings in Medicago Inc. During 2022, Medicago Inc. initiated additional rounds of equity funding in which PMIBV did not participate. As a result, PMIBV’s share of holdings in Medicago Inc. was reduced from approximately 23% as of December 31, 2021 to approximately 21% as of March 31, 2022. The guarantees are in effect through March 31, 2026.


Note 9. Income Taxes:
Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets.

PMI’s effective tax rates for the three months ended March 31, 2022 and 2021 were 19.7% and 21.5%, respectively. The effective tax rate for the three months ended March 31, 2022, was favorably impacted by changes in earnings mix by taxing jurisdiction, as well as a decrease in deferred tax liabilities related to the fair value adjustment of equity securities held by PMI ($13 million). For further details, see Note 12. Related Parties - Equity Investments and Other. The effective tax rate for the three months ended March 31, 2021, was favorably impacted by the corporate income tax rate reduction in Indonesia (enacted in the second quarter of 2020) and the Philippines (enacted in the first quarter of 2021), as well as changes in earnings mix by taxing jurisdiction. PMI estimates that its full-year 2022 effective tax rate will be 21% to 22%, excluding discrete tax events. Changes in currency exchange rates, earnings mix by taxing jurisdiction or future regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant judgment is required in determining income tax provisions and in evaluating tax positions.

PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of limitations remains open for the years 2017 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from 3 to 5 years. In October 2021, a subsidiary of PMI in Indonesia, PT Hanjaya Mandala Sampoerna Tbk ("HMS"), received a tax assessment in the amount of 3.8 trillion Indonesian rupiah (approximately $260 million) primarily relating to corporate income taxes on domestic and other intercompany transactions for the years 2017 to 2019. HMS paid the assessment in the fourth quarter of 2021 in order to avoid potential penalties and filed an objection letter with the tax office in January 2022. The amount paid was included in other assets in PMI’s condensed consolidated balance sheets at March 31, 2022 and December 31, 2021, and negatively impacted net cash provided by operating activities in the consolidated statements of cash flows in the period of payment.

It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits along with related interest and penalties. An estimate of any possible change cannot be made at this time.

34

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 10. Indebtedness:
Short-term Borrowings:
PMI's short-term borrowings, consisting of commercial paper and bank loans to certain PMI subsidiaries at March 31, 2022, and bank loans to certain PMI subsidiaries at December 31, 2021, had a carrying value of $2,441 million and $225 million, respectively. The fair values of PMI’s short-term borrowings, based on current market interest rates, approximate carrying value.


Long-term Debt:

At March 31, 2022 and December 31, 2021, PMI’s long-term debt consisted of the following:

(in millions) March 31, 2022 December 31, 2021
U.S. dollar notes, 0.875% to 6.375% (average interest rate 3.261%), due through 2044
$ 18,867  $ 19,397 
Foreign currency obligations:
Euro notes, 0.125% to 3.125% (average interest rate 1.995%), due through 2039
7,561  7,687 
Swiss franc notes, 1.625%, due 2024
270  273 
Other (average interest rate 3.238%), due through 2029 (a)
218  224 
Carrying value of long-term debt 26,916  27,581 
Less current portion of long-term debt 2,897  2,798 
  $ 24,019  $ 24,783 
(a) Includes mortgage debt in Switzerland as well as $68 million and $71 million in finance leases at March 31, 2022 and December 31, 2021, respectively.


35

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates currently available to PMI for issuances of debt with similar terms and remaining maturities. At March 31, 2022, the fair value of PMI's outstanding long-term debt, excluding the aforementioned finance leases, was as follows:

(in millions)
March 31, 2022
Level 1 $ 26,610 
Level 2 161 
For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2021.

Credit Facilities:

At March 31, 2022, PMI's total committed credit facilities were as follows:

(in billions)


Type
Committed
Credit
Facilities
364-day revolving credit, expiring January 31, 2023
$ 1.8 
Multi-year revolving credit, expiring February 10, 2026 (1)
2.0 
Multi-year revolving credit, expiring September 29, 2026 (2)
2.5 
Total facilities
$ 6.3 
(1) On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion.
(2) Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails to achieve, certain specified targets.

At March 31, 2022, there were no borrowings under these committed credit facilities, and the entire committed amounts were available for borrowing.

Note 11. Accumulated Other Comprehensive Losses:
PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
(Losses) Earnings At At At
(in millions) March 31, 2022 December 31, 2021 March 31, 2021
Currency translation adjustments $ (7,039) $ (6,701) $ (6,586)
Pension and other benefits (2,826) (2,880) (4,172)
Derivatives accounted for as hedges 105  12 
Total accumulated other comprehensive losses $ (9,760) $ (9,577) $ (10,746)
36

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Reclassifications from Other Comprehensive Earnings

The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period activity and reclassifications to the income statement, are shown on the condensed consolidated statements of comprehensive earnings for the three months ended March 31, 2022 and 2021. For additional information, see Note 3. Benefit Plans for disclosures related to PMI's pension and other benefits, Note 5. Financial Instruments for disclosures related to derivative financial instruments and Note 17. Acquisitions.

Note 12. Related Parties - Equity Investments and Other:

Equity Method Investments:

At March 31, 2022 and December 31, 2021, PMI had total equity method investments of $844 million and $879 million, respectively. Equity method investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or losses, dividends, capital contributions, changes in ownership interests and movements in currency translation adjustments. The carrying value of our equity method investments at March 31, 2022 and December 31, 2021, exceeded our share of the investees' book value by $724 million and $764 million, respectively. The difference between the investment carrying value and the amount of underlying equity in net assets, excluding $684 million and $728 million attributable to goodwill as of March 31, 2022 and December 31, 2021, respectively, which consists primarily of definite-lived intangible assets is being amortized on a straight-line basis. At March 31, 2022 and December 31, 2021, PMI received year-to-date dividends from equity method investees of $8 million and $176 million, respectively.

PMI holds a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia (Eastern Europe segment).

PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise Management et Développement des Actifs et des Ressources Holding ("MADAR Holding"), which manufactures and distributes under license some of PMI’s brands (Middle East & Africa segment).

The initial investments in Megapolis Distribution BV and EITA were recorded at cost and are included in equity investments on the condensed consolidated balance sheets.

Equity securities:

Following the deconsolidation of RBH on March 22, 2019, PMI recorded the continuing investment in RBH, PMI's wholly owned subsidiary in Canada, at fair value of $3,280 million at the date of deconsolidation, within equity investments. For further details, see Item 8, Note 20. Deconsolidation of RBH, in PMI's Annual Report on Form 10-K for the year ended December 31, 2021. Transactions between PMI and RBH are considered to be related party transactions from the date of deconsolidation and are included in the tables below.

The fair value of PMI’s other equity securities, which have been classified within Level 1, was $221 million at March 31, 2022. Unrealized pre-tax loss of $(60) million ($(47) million net of tax) on these equity securities was recorded in the condensed consolidated statement of earnings for the three months ended March 31, 2022.

Other related parties:

United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC ("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the Middle East & Africa segment. PMM sells, under license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI.

37

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Godfrey Phillips India Ltd ("GPI") is one of the non-controlling interest holders in IPM India, which is a 56.3% owned PMI consolidated subsidiary in the South & Southeast Asia segment. GPI also acts as contract manufacturer and distributor for IPM India. Amounts in the tables below include transactions between these related parties.

Financial activity with the above related parties:

PMI’s net revenues and expenses with the above related parties were as follows:
For the Three Months Ended March 31,
(in millions) 2022 2021
Net revenues:
Megapolis Group $ 387  $ 483 
Other 291  280 
Net revenues (a)
$ 678  $ 763 
Expenses:
Other $ 12  $ 17 
Expenses $ 12  $ 17 
(a) Net revenues exclude excise taxes and VAT billed to customers.

PMI’s balance sheet activity with the above related parties was as follows:
(in millions) At March 31, 2022
At December 31, 2021
Receivables:
Megapolis Group $ 455  $ 319 
Other 236  199 
Receivables $ 691  $ 518 
Payables:
Other $ 24  $ 25 
Payables $ 24  $ 25 
The activities with the above related parties are in the ordinary course of business, and are primarily for distribution, service fees, contract manufacturing and license agreements. PMI eliminated its respective share of all significant intercompany transactions with the equity method investees.


Note 13. Sale of Accounts Receivable:
To mitigate risk and enhance cash and liquidity management, PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing liability were not material as of March 31, 2022 and March 31, 2021. Under the non-servicing arrangements, PMI does not provide any administrative support or servicing after the trade receivables have been sold to the unaffiliated financial institutions.

Cumulative trade receivables sold, including excise taxes, for the three months ended March 31, 2022 and 2021, were $2.8 billion and $2.5 billion, respectively. PMI’s operating cash flows were positively impacted by the amount of the trade
38

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
receivables sold and derecognized from the condensed consolidated balance sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these arrangements as of March 31, 2022 and March 31, 2021, were $598 million, and $625 million, respectively. The net proceeds received are included in cash provided by operating activities in the condensed consolidated statements of cash flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of trade receivables within marketing, administration and research costs in the condensed consolidated statements of earnings. For the three months ended March 31, 2022 and 2021, the loss on sale of trade receivables was immaterial.

Note 14. Product Warranty:

PMI's heat-not-burn devices and e-vapor products are subject to standard product warranties generally for a period of 12 months from the date of purchase or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in future estimates. Factors that affect product warranties may vary across markets but typically include device version mix, product failure rates, logistics and service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At March 31, 2022 and December 31, 2021, these amounts were as follows:
(in millions) As of and For the Three Months Ended March 31, 2022 As of and For the Year Ended December 31, 2021
Balance at beginning of period $ 113  $ 137 
Changes due to:
   Warranties issued 46  154 
    Settlements (26) (177)
    Currency/Other (3) (1)
Balance at end of period $ 130  $ 113 

Note 15. Leases:

The components of PMI’s lease cost were as follows for the three months ended March 31, 2022 and 2021:
For the Three Months Ended March 31,
(in millions) 2022 2021
Operating lease cost $ 62  $ 60 
Finance lease cost:
Amortization of right-of-use assets 16 
Interest on lease liabilities
—  — 
Short-term lease cost 14  10 
Variable lease cost
Total lease cost $ 98  $ 85 

Note 16. Asset Impairment and Exit Costs:

For the three months ended March 31, 2022, PMI did not record any pre-tax charges for asset impairment and exit costs. For the three months ended March 31, 2021, PMI recorded total pre-tax asset impairment and exit costs of $48 million. These pre-tax charges for the three months ended March 31, 2021 were included in marketing, administration and research costs in the condensed consolidated statements of earnings.

39

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
South Korea

In the first quarter of 2021, PM Korea commenced the implementation of a new business operating model, which required the restructuring of its current distribution agreements. As a result, PMI recorded exit costs of $26 million in the three months ended March 31, 2021, related to contract terminations and restructuring with certain distributors.

Organizational Design Optimization

As part of PMI’s transformation to a smoke-free future, PMI sought to optimize its organizational design, which included the elimination, relocation and outsourcing of certain operations center and centralized activities. In January 2020, PMI commenced a multi-phase restructuring project in Switzerland. PMI initiated the employee consultation procedures, as required under Swiss law, for the impacted employees. The consultation procedures for the first two phases were completed in 2020 with the final phases initiated and completed in 2021. Additionally, since the commencement of this multi-phase restructuring project in 2020, PMI launched a voluntary separation program in Switzerland for certain eligible employees and announced the outsourcing of certain activities in Argentina, Indonesia, Poland and the United States. This multi-phase restructuring project was completed in the fourth quarter of 2021.

For the three months ended March 31, 2021, PMI recorded pre-tax charges of $22 million, related to the organizational design optimization. Since inception of this multi-phase restructuring project in January 2020 through December 31, 2021, approximately 1,020 positions in total were impacted, resulting in cumulative pre-tax charges of $308 million related to the organizational design optimization program. Of this cumulative pre-tax amount, $300 million related to separation program charges and $8 million related to asset impairment charges.

Asset Impairment and Exit Costs by Segment

PMI recorded the following pre-tax asset impairment and exit costs by segment:

(in millions) For the Three Months Ended March 31,
  2021
Separation programs: (1)
European Union $
Eastern Europe
Middle East & Africa
South & Southeast Asia
East Asia & Australia
Americas
Total separation programs 22 
Contract termination charges:
East Asia & Australia 26 
Total contract termination charges 26 
Asset impairment and exit costs $ 48 
(1) Organizational design optimization pre-tax charges in 2021 were allocated across all geographical segments.

40

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Movement in Exit Cost Liabilities

The movement in exit cost liabilities for the three months ended March 31, 2022 was as follows:
(in millions)  
Liability balance, January 1, 2022 $ 142 
Charges, net — 
Cash spent (28)
Currency/other (1)
Liability balance, March 31, 2022 $ 113 

Future cash payments for exit costs incurred to date are anticipated to be substantially paid by the end of 2023, with approximately $72 million expected to be paid in the remainder of 2022.


Note 17. Acquisitions:

Purchase of Noncontrolling Interests

Turkey – In the first quarter of 2022, PMI acquired the remaining 25% stake of its holding in Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş. (formerly Philsa Philip Morris Sabancı Sigara ve Tütüncülük Sanayi ve Ticaret A.Ş.) and 24.75% stake in Philip Morris Pazarlama ve Satış A.Ş. (formerly Philip Morris SA, Philip Morris Sabancı Pazarlama ve Satış A.Ş.) from its Turkish partners, Sabanci Holding for a total acquisition price including transaction costs and remaining dividend entitlements of approximately $223 million. As a result of this acquisition, PMI now owns 100% of these Turkish subsidiaries. The purchase of the remaining stakes in these holdings resulted in a decrease to PMI's additional paid-in capital of $30 million and an increase to accumulated other comprehensive losses of $171 million primarily following the reclassification of accumulated currency translation losses from noncontrolling interests to PMI’s accumulated other comprehensive losses during the first quarter of 2022.

Business Combinations

AG Snus - On May 6, 2021, PMI acquired 100% of AG Snus Aktieselskab ("AG Snus"), a company based in Denmark, and its Swedish subsidiary Tobacco House of Sweden AB fully owned by AG Snus, which operates in the oral tobacco (i.e. snus) and modern oral (i.e. nicotine pouches) product categories. The purchase price was $28 million in cash, net of cash acquired, with additional contingent payments of up to $10 million, primarily relating to product development and performance targets over a less than two-year period. The operating results of AG Snus are included in the European Union segment, and were not material.

Fertin Pharma – On September 15, 2021, PMI acquired 100% of Fertin Pharma A/S (“Fertin Pharma”), a company based in Denmark. Fertin Pharma is a developer and manufacturer of pharmaceutical and well-being products based on oral and intra-oral delivery systems. The acquisition was funded with existing cash. The total consideration of $821 million (DKK 5.2 billion) included cash of $580 million and the payment of $241 million related to the settlement of Fertin Pharma’s indebtedness. The purchase price of $821 million was preliminarily allocated to cash ($24 million), current assets including receivables and inventories ($69 million), non-current assets including property, plant and equipment ($228 million), goodwill ($378 million), and other intangible assets ($245 million, which primarily consisted of customer relationships, developed technology, and in process research and development ("IPR&D")), partially offset by current liabilities ($44 million, which primarily consisted of accrued liabilities and accounts payable) and non-current liabilities ($79 million, primarily deferred income tax). Goodwill is primarily attributable to future growth opportunities provided by acquired R&D capabilities and any intangibles that did not qualify for separate recognition. The amortizable intangible assets are being amortized over their estimated useful lives of 8 to 19 years. During the first quarter of 2022, PMI did not record any measurement period adjustments to the preliminary purchase price allocation. The purchase price allocation is preliminary and continues to be subject to refinement. PMI is evaluating the deductibility of goodwill for income tax purposes.
41

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Vectura – During the third quarter and up to September 15, 2021, PMI acquired a controlling interest of 74.77% of the total issued shares in Vectura Group plc (“Vectura”), an inhaled therapeutics company based in the United Kingdom. The shares were acquired through a series of open market purchases and acceptances of the tender offer at a price of 165 pence per share. As a result of additional acceptances of the offer and the exercise of the right to acquire compulsorily the Vectura shares, in accordance with the applicable English law, PMI completed the acquisition of 100% of Vectura in the fourth quarter of 2021. The acquisition was funded with existing cash from a designated account operated solely for the purpose of funding this acquisition.

The total purchase price of $1,384 million (GBP 1.0 billion) for 100% of the Vectura shares was preliminarily allocated to cash ($136 million), current assets including receivables and inventories ($89 million), non-current assets including property, plant and equipment ($67 million), goodwill ($590 million), and other intangible assets ($719 million, which primarily consisted of developed technology, and IPR&D), partially offset by current liabilities ($100 million, primarily accrued liabilities), and non-current liabilities ($117 million, primarily deferred income tax). Goodwill is primarily attributable to future growth opportunities provided by acquired R&D capabilities and any intangibles that did not qualify for separate recognition. The amortizable intangible assets are being amortized over their estimated useful lives of 3 to 15 years. During the first quarter of 2022, PMI did not record any measurement period adjustments to the preliminary purchase price allocation. The purchase price allocation is preliminary and continues to be subject to refinement. PMI is evaluating the deductibility of goodwill for income tax purposes.

Pro forma results of operations for the above business combinations have not been presented as the aggregate impact is not material to PMI's consolidated statements of earnings.

Asset Acquisition

On August 9, 2021, PMI acquired 100% of OtiTopic, Inc., a U.S. respiratory drug development company with a late-stage dry powder inhalation aspirin treatment for acute myocardial infarction. The transaction price was $38 million in cash, plus transaction costs, with additional contingent payment of $13 million, primarily related to certain key milestones that PMI deemed probable. Additionally, PMI may owe up to $25 million in future additional contingent payments dependent upon the achievement of certain milestones. PMI accounted for this transaction as an asset acquisition since the IPR&D of the dry powder inhalation aspirin treatment represented substantially all of the fair value of the gross assets acquired. At the date of acquisition, PMI determined that the acquired IPR&D had no alternative future use. As a result, PMI recorded a charge of $51 million to research and development costs within marketing, administration and research costs in the third quarter of 2021.

As previously discussed in Note 1. Background and Basis of Presentation and Note 7. Segment Reporting, on March 31, 2022, PMI launched a new Wellness and Healthcare business, Vectura Fertin Pharma, which consolidates Fertin Pharma, Vectura and OtiTopic, Inc. This business is considered one operating segment with its operating results included in the Other category.




















42

Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)


Note 18. War in Ukraine:

In February 2022, the Russian Federation launched a military action against Ukraine. Since the onset of the war in Ukraine, PMI's main priority has been the safety and security of its more than 1,300 employees and their families in the country.
Ukraine

PMI temporarily suspended its operations in Ukraine, including the closing of its factory in Kharkiv at the end of February 2022. While the effects of the war are unpredictable and could trigger impairment reviews for long-lived assets, as of March 31, 2022, PMI is unable to estimate the information required to perform impairment analyses (i.e., forecast of revenues, manufacturing and commercial plans). PMI is not aware of any major damage to its production facilities, inventories or other assets in Ukraine. As a result, PMI has not recorded an impairment of long-lived assets. As of March 31, 2022, PMI’s Ukrainian operations had approximately $0.4 billion in total assets, excluding intercompany balances. These total assets included $105 million, $192 million and $44 million in receivables, inventories and property, plant and equipment, respectively.

As of March 31, 2022, PMI recorded in its condensed consolidated statements of earnings a pre-tax charge related to circumstances driven by the conflict of $27 million, primarily due to an inventory write down, additional allowance for receivables and the cost of PMI’s humanitarian efforts, which includes salary continuation for its employees.

Russia

PMI has suspended its planned investments in the Russian Federation including all new product launches and commercial, innovation, and manufacturing investments. PMI has also initiated plans to scale down its manufacturing operations in Russia amid ongoing supply chain disruptions and the evolving regulatory environment and is working on options to exit the Russian market in an orderly manner. As a result of PMI continuing operations within Russia as of March 31, 2022, it has not recorded an impairment of long-lived and other assets. PMI’s Russian operations as of March 31, 2022 had approximately $1.4 billion in total assets, excluding intercompany balances. These total assets included $464 million, $487 million and $357 million in receivables, inventories and property, plant and equipment, respectively.

As of March 31, 2022, PMI recorded in its condensed consolidated statements of earnings a pre-tax charge related to circumstances driven by the conflict of $15 million, which was primarily due to an inventory write down related to the commercial decisions noted above.

The pre-tax charges, for both PMI’s Ukrainian and Russian affiliates, of $26 million and $16 million were recorded in cost of sales and marketing, administration and research costs, respectively. PMI will continue to monitor the situation as it evolves and will determine if further charges are needed.
43

Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Description of Our Company

We are a leading international tobacco company working to deliver a smoke-free future and evolving our portfolio for the long-term to include products outside of the tobacco and nicotine sector. Our current product portfolio primarily consists of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. Since 2008, we have invested more than $9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration ("FDA") has authorized the marketing of versions of our IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. We describe the MRTP orders in more detail in the "Business Environment" section of this Item 2. With a strong foundation and significant expertise in life sciences, in February 2021, we announced our ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs.

We currently manage our business in six geographical segments and an Other category:

European Union ("EU");
Eastern Europe ("EE");
Middle East & Africa ("ME&A"), which includes our international duty free business;
South & Southeast Asia ("S&SA");
East Asia & Australia ("EA&A");
Americas ("AMCS"); and
Other, which includes the operating results of our new Wellness and Healthcare business. In the third quarter of 2021, we acquired Fertin Pharma A/S, Vectura Group plc. (also known as Vectura Group Ltd.) and OtiTopic, Inc. On March 31, 2022, we launched a new Wellness and Healthcare business consolidating these entities, Vectura Fertin Pharma. The operating results of this new business is reported in this Other category. For further details, see Note 7. Segment Reporting and Note 17. Acquisitions.

Our cigarettes are sold in approximately 180 markets, and in many of these markets they hold the number one or number two market share position. We have a wide range of premium, mid-price and low-price brands. Our portfolio comprises both international and local brands.

In addition to the manufacture and sale of cigarettes, we are engaged in the development and commercialization of reduced-risk products ("RRPs"). RRPs is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking.  IQOS is the leading brand in our smoke-free product portfolio. As of March 31, 2022, our smoke-free products were available for sale in 71 markets in key cities or nationwide.

During 2021, we laid the foundation for our long-term growth ambitions beyond nicotine in wellness and healthcare, including the milestone acquisitions of Vectura Group plc and Fertin Pharma A/S, as noted above, which provide essential capabilities for future product development.

We use the term net revenues to refer to our operating revenues from the sale of our products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. Our net revenues and operating income are affected by various factors, including the volume of products we sell, the price of our products, changes in currency exchange rates and the mix of products we sell. Mix is a term used to refer to the proportionate value of premium-price brands to mid-price or low-price brands in any given market (product mix). Mix can also refer to the proportion of shipment volume in more profitable markets versus shipment volume in less profitable markets (geographic mix).

44

Our cost of sales consists principally of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost of devices produced by third-party electronics manufacturing service providers. Estimated costs associated with device warranty programs are generally provided for in cost of sales in the period the related revenues are recognized.

Our marketing, administration and research costs include the costs of marketing and selling our products, other costs generally not related to the manufacture of our products (including general corporate expenses), and costs incurred to develop new products. The most significant components of our marketing, administration and research costs are marketing and sales expenses and general and administrative expenses.
Philip Morris International Inc. is a legal entity separate and distinct from its direct and indirect subsidiaries. Accordingly, our right, and thus the right of our creditors and stockholders, to participate in any distribution of the assets or earnings of any subsidiary is subject to the prior rights of creditors of such subsidiary, except to the extent that claims of our company itself as a creditor may be recognized. As a holding company, our principal sources of funds, including funds to make payment on our debt securities, are from the receipt of dividends and repayment of debt from our subsidiaries. Our principal wholly owned and majority-owned subsidiaries currently are not limited by long-term debt or other agreements in their ability to pay cash dividends or to make other distributions that are otherwise compliant with law.

Executive Summary
The following executive summary provides the business update and significant highlights from the "Discussion and Analysis" that follows.
War in Ukraine

Since the onset of the war in Ukraine, our main priority has been the safety and security of our more than 1,300 employees and their families in the country. We have taken action to achieve three critical missions: (i) helping to evacuate more than 1,000 people from Ukraine and relocate over 2,700 others from conflict zones to locations in the country away from the heaviest fighting; (ii) providing critical aid to employees who cannot leave or who decide to remain in Ukraine; and (iii) providing those who have left the country with logistical, medical, financial, and other practical support in neighboring countries. We are continuing to pay salaries to all our Ukrainian employees and are also providing substantial in-kind support to them and their families. In addition, we have already contributed around $10 million in funds and donated essential items across the country, directly to humanitarian organizations and through our own employee-led initiative, Projects With a Heart.
On February 25, 2022, we announced the temporary suspension of our operations in Ukraine, including at our factory in Kharkiv. While activities in the east of Ukraine remain the most heavily impacted, we have seen some resumption of retail activities where safety allows, as we seek to provide product availability and service to adult consumers, using existing finished goods inventories on hand. We are also working on future supply from other production centers, although this may involve higher costs. We are applying increased security and safety measures for personnel.
In 2021, Ukraine accounted for around 2% of our total cigarette and heated tobacco unit shipment volume and under 2% of our total net revenues. As of March 31, 2022, our Ukrainian operations had approximately $0.4 billion in total assets, excluding intercompany balances.
On March 24, 2022, we announced concrete steps we had taken to suspend planned investments and scale down our manufacturing operations in Russia. This included:
the discontinuation of a number of cigarette products offered in the market (representing approximately one-quarter of the company's domestic cigarette SKUs, including Marlboro and Parliament SKUs) and the reduction of our manufacturing activities accordingly;
the suspension of our marketing activities in the country;
the cancellation of all product launches planned for 2022 in the market, including the launch of its flagship heated tobacco product IQOS ILUMA, originally planned for March 2022; and
the cancellation of our plans to manufacture TEREA heated tobacco units for IQOS ILUMA in Russia (with an eventual annualized capacity of more than 20 billion units) and the related ongoing investment of $150 million.
45

Further, we announced that our Board of Directors and senior executives are working on options to exit the Russian market in an orderly manner, in the context of an increasingly complex and rapidly changing regulatory and operating environment.
We employ more than 3,200 people in Russia and will continue to support our employees there, including paying their salaries, while continuing to fulfill our legal obligations. We will continue to make decisions with their safety and security as a priority.
In 2021, Russia made up almost 10% of total shipment volumes and around 6% of our total net revenues. As of March 31, 2022, our Russian operations had approximately $1.4 billion in total assets, excluding intercompany balances.

These developments above have and will continue to have a material adverse impact on our business, results of operations, cash flows and financial position, and may result in impairment charges.
For further details, see Note 18. War in Ukraine to our condensed consolidated financial statements and the "Cautionary Factors That May Affect Future Results" section of this MD&A.

Consolidated Operating Results for the Three Months Ended March 31, 2022

Net Revenues - Net revenues of $7.7 billion for the three months ended March 31, 2022 increased by $161 million, or 2.1%, from the comparable 2021 amount. The change in our net revenues from the comparable 2021 amount was driven by the following (variances not to scale with quarterly results):
pm-20220331_g1.jpg
During the quarter, net revenues, excluding currency and acquisitions, increased by 9.0%, mainly reflecting: favorable volume/mix, primarily driven by higher heated tobacco unit volume (predominantly in the EU, particularly Germany, Italy and Poland), higher cigarette volume (mainly in Indonesia, PMI Duty Free and the Philippines, partly offset by Germany and Russia) and higher device volume (driven by the EU and Japan), partially offset by unfavorable cigarette mix (mainly in Japan); and a favorable pricing variance (notably driven by Germany, Russia and Turkey, partly offset by Indonesia and the Philippines).

During the quarter, Russia and Ukraine accounted for around 6% of PMI's total net revenues.
46


Net revenues by product category for the three months ended March 31, 2022 and 2021, are shown below:

pm-20220331_g2.jpg        pm-20220331_g3.jpg


Diluted Earnings Per Share - The changes in our reported diluted earnings per share ("diluted EPS") for the three months ended March 31, 2022, from the comparable 2021 amounts, were as follows:
Diluted EPS % Change
For the three months ended March 31, 2021 $ 1.55 
2021 Asset impairment and exit costs 0.02 
2021 Tax items — 
       Subtotal of 2021 items 0.02 
2022 Charges related to the war in Ukraine
(0.03)
2022 Fair value adjustment for equity security investments (0.03)
2022 Tax items — 
       Subtotal of 2022 items (0.06)
Currency (0.23)
Interest 0.01 
Change in tax rate 0.03 
Operations 0.18 
For the three months ended March 31, 2022 $ 1.50  (3.2) %

Asset impairment and exit costs – In the first quarter of 2021, we recorded pre-tax asset impairment and exit costs of $48 million, representing $38 million net of income tax and a diluted EPS charge of $0.02 per share, related to product distribution restructuring in South Korea and the organizational design optimization plan, primarily in Switzerland. The total pre-tax charge was included in marketing, administration and research costs on the condensed consolidated statements of earnings. For further details, see Note 16. Asset Impairment and Exit Costs.

Charges related to the war in Ukraine – In the first quarter of 2022, we recorded a pre-tax charge of $42 million, representing $39 million net of income tax and a diluted EPS charge of $0.03 per share, related to circumstances driven by the conflict, including inventory write downs, additional allowances for receivables and the cost of PMI’s humanitarian efforts. Of this total pre-tax charge, $26 million was recorded in cost of sales and $16 million was recorded in marketing, administration and research costs. For further details, see Note 18. War in Ukraine.

47

Fair value adjustment for equity security investments – In the first quarter of 2022, we recorded an unfavorable fair value adjustment for our equity security investments in India and Sri Lanka of $47 million after tax (or $0.03 per share decrease in diluted EPS). The fair value adjustment for our equity security investments was included in equity investments and securities (income)/loss, net ($60 million loss) and provision for income taxes ($13 million benefit) on the condensed consolidated statements of earnings for the three months ended March 31, 2022. For further details, see Note 12. Related Parties - Equity Investments and Other.

Income Taxes – The change in the tax rate that increased our diluted EPS by $0.03 per share in the table above was primarily due to changes in earnings mix by taxing jurisdiction.

Currency – The unfavorable impact of $0.23 per share during the reporting period primarily results from the fluctuations of the U.S. dollar, especially against the Euro, Japanese yen and Turkish lira. This unfavorable currency movement has impacted our profitability across our primary revenue markets and local currency cost bases.

Operations – The increase in diluted EPS of $0.18 from our operations in the table above was due primarily to the following segments:

Middle East & Africa: Favorable pricing, favorable volume/mix and lower marketing, administration and research costs, partially offset by higher manufacturing costs; and
European Union: Favorable volume/mix, partially offset by higher manufacturing costs;
partially offset by
East Asia & Australia: Unfavorable volume/mix and higher manufacturing costs, partially offset by lower marketing, administration and research costs and favorable pricing;
South & Southeast Asia: Unfavorable pricing, partially offset by favorable volume/mix;
Eastern Europe: Unfavorable volume/mix and higher marketing, administration and research costs, partially offset by favorable pricing;
Americas: Higher manufacturing costs and unfavorable volume/mix, partially offset by favorable pricing; and
Other: Primarily reflecting the amortization of intangibles related to the acquisitions, investments in research and development, and expenses related to employee retention programs.
For further details, see the “Consolidated Operating Results” and “Operating Results by Business Segment” sections of the following “Discussion and Analysis.”


48

Discussion and Analysis
Consolidated Operating Results
See pages 82-92 for a discussion of our "Cautionary Factors That May Affect Future Results." Our net revenues and operating income by segment are shown in the table below:
(in millions) For the Three Months Ended March 31,
2022 2021 Change
Net revenues:
European Union $ 3,012  $ 2,909  3.5  %
Eastern Europe 726  796  (8.8) %
Middle East & Africa 991  801  23.7  %
South & Southeast Asia 1,123  1,173  (4.3) %
East Asia & Australia 1,404  1,472  (4.6) %
Americas 424  434  (2.3) %
Other 66  —  —  %
Net revenues $ 7,746  $ 7,585  2.1  %
Operating income (loss):
European Union $ 1,527  $ 1,490  2.5